No retraction, correction or concern found when last checked on Oct 24, 2026.

Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future

Olayinka O. Ogunleye, Debashis Basu, Debjani Mueller and 69 more

Frontiers in Pharmacology · 2020 · Review · CC BY

doi:10.3389/fphar.2020.01205

Abstract

Background. The COVID-19 pandemic has already claimed considerable lives. There are major concerns in Africa due to existing high prevalence rates for both infectious and non-infectious diseases and limited resources in terms of personnel, beds and equipment. Alongside this, concerns that lockdown and other measures will have on prevention and management of other infectious diseases and non-communicable diseases (NCDs). NCDs are an increasing issue with rising morbidity and mortality rates. The World Health Organization (WHO) warns that a lack of nets and treatment could result in up to 18 million additional cases of malaria and up to 30,000 additional deaths in sub-Saharan Africa.

Objective. Document current prevalence and mortality rates from COVID-19 alongside economic and other measures to reduce its spread and impact across Africa. In addition, suggested ways forward among all key stakeholder groups.

Our Approach. Contextualise the findings from a wide range of publications including internet-based publications coupled with input from senior-level personnel.

Ongoing Activities. Prevalence and mortality rates are currently lower in Africa than among several Western countries and the USA. This could be due to a number of factors including early instigation of lockdown and border closures, the younger age of the population, lack of robust reporting systems and as yet unidentified genetic and other factors. Innovation is accelerating to address concerns with available equipment. There are ongoing steps to address the level of misinformation and its consequences including fines. There are also ongoing initiatives across Africa to start addressing the unintended consequences of COVID-19 activities including lockdown measures and their impact on NCDs including the likely rise in mental health disorders, exacerbated by increasing stigma associated with COVID-19. Strategies include extending prescription lengths, telemedicine and encouraging vaccination. However, these need to be accelerated to prevent increased morbidity and mortality.

Conclusion. There are multiple activities across Africa to reduce the spread of COVID-19 and address misinformation, which can have catastrophic consequences, assisted by the WHO and others, which appear to be working in a number of countries. Research is ongoing to clarify the unintended consequences given ongoing concerns to guide future activities. Countries are learning from each other.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

COVID-19 and Key Risk Factors

1The novel coronavirus named SARS-CoV-2 causing COVID-19 was first reported in Hubei Province in China in December 2019, and has subsequently spread to all continents. COVID-19 is transmitted from person to person through respiratory droplets as well as directly through touching surfaces and other fomites. Initial observations from China suggested a case fatality ratio (CFR) of 2.3%. In their July 1, 2020 report, the World Health Organization (WHO) suggested a case fatality ratio (CFR) of 4.91% based on 10,357,662 confirmed cases worldwide and 508,055 recorded deaths.

2Increased morbidity and case fatality from COVID-19 is associated with a number of underlying health conditions, alongside male gender and older age. These include hypertension, cardiovascular disease (CVD), diabetes, obesity, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and history of smoking and shortness of breath, as well as some immunosuppressive conditions and potentially blood type. Ethnicity, particularly for people of Black Afro-Caribbean origin alongside those from South Asia, has also emerged as a significant factor associated with a higher mortality risk versus the white population in Europe and the United States of America (USA). However, it is currently not fully understood how ethnicity, poverty and deprivation, cultural and behavioral differences, as well as underlying health, interplay in morbidity or mortality risk especially with currently lower mortality rates in Africa at the end of June 2020 compared with a number of European countries and the USA.

Prevention and Treatment of COVID-19

3Response activities to the COVID-19 pandemic typically included personal protection through physical distancing and hand washing coupled with respiratory precautions through face covering. Increased testing and screening with contact tracing are fundamental to transmission control, and this has been variably combined with “locking down” of public places including educational establishments, retail outlets, factories and offices combined with closure of borders and quarantining suspected persons. Case management of patients includes supportive care with supplementary oxygen coupled with ventilatory support for those most severely affected. Depending on the threshold for hospital admission, it is estimated that up to 17% of hospitalized patients will require intensive care, with an appreciable proportion needing mechanical ventilation. This is a concern even in high-income countries where there have been challenges with the availability of critical care beds, appropriately trained staff and personal protective equipment (PPE).

4An encouraging example of a positive response among low- and middle- income countries (LMICs) is Vietnam where multiple activities including extensive testing, contact tracing, and social distancing, under the government slogan “Fighting the epidemic is like fighting against the enemy”, have been successful in limiting the tranmission of COVID-19 with only 355 confirmed cases by the end of June 2020 and no recorded attributable mortality.

5Currently, there does not appear to be a cure for COVID-19; however, there are a number of medicines undergoing trials including antivirals, steroids, antimalarials, immunomodulators, and herbal medicines, some of which have shown positive findings although there have been concerns with the trial design of a number of studies.

6The most promising therapeutic breakthrough to date has come from the UK-based adaptive randomised Recovery trial. The low cost corticosteroid dexamethasone has recently been shown to significantly reduce mortality in the most severely affected patients with COVID-19; patients with an oxygen requirement and those requiring ventilatory support. Other recent studies have also shown benefit from corticosteroids in critically ill patients increasing the number of days alive and free of mechanical ventilation as well as reducing mortality. The prescribing of 6mg of dexamethasone daily for 10 days is now recommended for widespread use in the UK unless contraindicated for other reasons as well as endorsed by the National Institute of Health (NIH) in the USA. However, currently optimal dosing and duration of dexamethasone in COVID-19 is unknown; consequently, current recommendations reflect those used in the Recovery trial.

7Initial studies with remdesivir failed to demonstrate clinical benefit over placebo although these were underpowered. More recently, larger scale studies conducted by NIH in the USA have shown encouraging results including a reduction in the time to recovery and a trend towards lower mortality (hazard ratio for death = 0.70) leading to the issuance of an Emergency Use Authorization by the US FDA as well as endorsement by the European Medicines Agency and the NHS in the UK. However, further studies are needed before the prescribing of remdesivir can be fully endorsed.

8However, much controversy surrounds the use of chloroquine and hydroxychloroquine with or without azithromycin for both the prevention and treatment of COVID-19. Following initial studies in China, coupled with the findings of Gautret et al. (2020), its use was endorsed among a number of governments and medical societies. However, the lack of a comparator arm in the initial studies has been heavily criticised coupled with concerns with side-effects including cardiac side-effects with hydroxychloroquine as well as reports of fatal overdoses. Recent studies have failed to demonstrate any clinical benefit for both the prevention and treatment of COVID-19. The study by Mehra et al. also showed increased mortality with chloroquine or hydroxychloroquine; however, this has now been retracted subject to external auditing. The European Medicines Agency now advises caution with the prescribing of hydroxychloroquine outside of clinical trials, and the WHO has halted the hydroxychloroquine arm in its ongoing Solidarity Trial with the NIH in the USA also halting the use of hydroxychloroquine in its studies. In South Africa, the South African Pharmacy Council has also warned against the misuse of hydroxychloroquine for the treatment of COVID-19, which builds on concerns from the regulatory agency given the lack of evidence.

9The antiretroviral treatment (ART) lopinavir-ritonavir, which showed activity against MERS-CoV, has also been recommended for treating COVID-19 patients alongside arbidol. However, there have also been contrasting data regarding its effectiveness in COVID-19 patients, with most studies failing to show any clinical benefit including the UK Recovery study. Consequently, lopinavir-ritonavir cannot currently be recommended for use outside of clinical trials and more recently the WHO has discontinued the lopinavir-ritonavir arm in the Solidarity Trial. A recent study though by Hung et al. (2020) found that early triple antiviral therapy with interferon beta-1b, lopinavir/ritonavir and ribavirin alleviated the symptoms and shortened the duration of viral shedding and hospital stay compared with lopinavir/ ritonavir alone in patients with mild to moderate COVID-19. Any positive findings though with combination therapies need confirmation before they can be endorsed. Studies regarding the potential effectiveness of nasal irrigation are also ongoing. This follows a pilot randomised study showing improvements in the duration of symptoms and viral shedding in patients with upper respiratory tract infections, with a post-hoc re-analysis with a focus on those infected with coronaviruses also showing benefit.

10A number of other treatments focusing on the late inflammatory complications of COVID-19 are also under review. These include tocilizumab, which is widely used in rheumatoid arthritis and blocks Interleukin-6 (IL-6), a combination of emapalumab, anakinra and sarilumab, and interferons. These are currently not recommended for use outside of clinical trials. Ongoing studies are also using the plasma from affected patients along with prior titration of neutralising antibodies, and anticoagulants for hypercoagulability states. Again, these experimental therapies cannot be recommended until more clinical trial data becomes available.

11There has also been controversy surrounding BCG vaccination as possible protection against COVID-19. The WHO is warning against claims of effectiveness based on current ecological studies, with the South African Government and leading scientists also warning against diverting stocks away from neonatal vaccination programmes given concerns with shortages until more trial data becomes available.

12There are also concerns with the inappropriate use of medicinal plants to prevent and treat COVID-19, which such use particularly prevalent in some sub-Saharan African countries as this can cause more harm than good. Safety fears are enhanced by the lack of data when used to prevent or treat COVID-19 along with other treatments that patients may be taking including antivirals, antibiotics as well as medicines for non-communicable diseases (NCDs). We are aware that some herbal medicines are showing promise based on in vitro and small-scale clinical studies. However, their use outside of such studies is a concern until more data becomes available especially if their use causes delay in patients seeking appropriate care from healthcare professionals as their symptoms develop.

13The controversies and issues surrounding a number of the treatments, the redaction of recent studies, as well as concerns with trial design in a number of studies, means it is essential that treatment recommendations should only be made once the results of robust trials are known.

Consequences of Lockdown and Other Measures to Prevent and Treat COVID-19

14There are a number of unintended consequences arising from COVID-19. These include Governments diverting personnel and resources away from priority diseases including both infectious and non-infectious diseases. Reducing antimicrobial resistance (AMR) is a key activity across countries especially among LMICs as it increases morbidity, mortality and costs. However, diverting attention away from AMR, including ongoing efforts to reduce inappropriate self-purchasing of antibiotics, which is prevalent across many countries, as well as routine immunisation programmes for existing infectious diseases, will inevitably have a significant impact on future patient care. Self-purchasing of antibiotics is a particular concern with the clinical presentation of COVID-19 overlapping with other infectious diseases including tuberculosis (TB), viral and bacterial respiratory tract infections, and pneumonia, making a differential diagnosis challenging exacerbated by limited diagnostic facilities in most communities. In hospitals, establishing antimicrobial stewardship programmes and other activities can improve antibiotic prescribing where there is little evidence of bacterial co-infection. Consequently, it is essential that such activities be introduced where necessary to guide future antibiotic prescribing among suspected COVID-19 patients.

15We are aware that the Ebola outbreak in Guinea, Liberia, and Sierra Leone between 2014 and 2016 resulted in as many people dying from HIV/AIDS, TB, and malaria as Ebola due to reduced access to health care. There are also concerns that an appreciable reduction in the distribution of protective bed nets (75%) and medicines for treating malaria due to lockdown measures, combined with no media campaigns, could result in up to 18 million additional cases and up to 30,000 additional deaths in sub-Saharan Africa alone compared to 2018. Whilst the latest evidence suggests that HIV positive patients do not have a higher COVID-19 infection rate, or a significantly different disease course than HIV-negative individuals, patients’ fears of contracting COVID-19 when they attend clinics, as well as limited access to health facilities and treatment during lockdown, will negatively impact on treatment and adherence to medicines as well as initial diagnosis. Medicine supplies can potentially be addressed through differentiated service delivery and other programmes. Telemedicine and other technologies could also potentially help with consultations, with mobile technologies helping with tracking and tracing COVID-19 patients.

16There are also concerns that lockdown measures will negatively impact of the management of patients with non-communicable diseases (NCDs). This includes a lack of support and access to facilities to improve lifestyle management, monitor patient and regularly provide essential medicines. Ongoing national plans to reduce morbidity and mortality due to NCDs, especially CVD and diabetes, across continents including Africa could also be compromised by reduced access to medicines, cancelled or missed appointments due to patients' reduced access to facilities and fear of coming into contact with COVID-19 patients in healthcare facilities, and not following lifestyle advice. However, we are aware that governments are committing extra resources to try and minimise these unintended consequences. Issues relating to medical supplies can again be addressed by measures to extend prescription lengths as well as home delivery of medicines, with concerns with consultations potentially addressed through technologies such as telemedicine.

17Other serious consequences include the exacerbation of mental health conditions during lockdown, the implications for frontline healthcare workers in terms of their health and wellbeing, and anxiety of citizens about their health. Patients with COVID-19 are also at increased risk of requiring psychotropic medicines because mild-to-moderate illness may result in adverse psychological effects from the diagnosis, from the symptoms, the need for forced isolation, any associated loss of income, and the potential risk of death. This might trigger new psychiatric symptoms or exacerbate underlying psychiatric conditions. In moderate-to-severe clinical situations, there is a risk that patients could develop altered states of consciousness such as hypo- or hyperkinetic delirium, which may require treatment with psychotropic medications. In addition, some of the medical treatments that have been proposed for COVID-19 could contribute to onset or worsening of psychiatric symptoms. These include psychiatric disturbances with antivirals and steroids as well as depressive-dysphoric experiences with interferons.

18In addition, patients with existing mental illnesses may well have difficulties with accessing regular help during the pandemic unless pro-actively addressed. This includes continued access to medicines and treatments for those with long-term mental health conditions since sudden discontinuation should be avoided. Worsening of mental health may be greater in patients with conditions such as schizophrenia with challenges in continuing active case management in the community during the pandemic as well as concerns with administering long-acting injections where pertinent, and performing regular blood tests in patients prescribed clozapine. Pro-active and timely support is needed for all patients with mental health conditions to avoid deteriorating conditions. There are also reports of an increase in gender-based violence across countries, including African countries, as a result of lockdown measures, which also needs addressing going forward.

Specific Challenges of COVID-19 in Africa

19COVID-19 poses a particular challenge for the African continent because of existing high prevalence rates of other infectious diseases including human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS), TB, cholera, and malaria, along with high rates of AMR and a disproportionate burden of poverty, with ongoing infectious disease initiatives appreciably challenged by COVID-19. The presence of multi-morbidity with NCDs will aggravate the situation further, with already high rates of CVD and diabetes a growing concern across Africa.

20Alongside this, there are ongoing challenges with available financial and human resources across Africa including more limited availability of healthcare personnel and hospital beds including intensive care unit (ICU) beds. Reports suggest there were just 1.8 hospital beds per 1,000 people across Africa before the pandemic, less than a third of those in France. Oxygen is also not widely available and single room isolation can be a rarity making nosocomial transmission a concern. Overall, there appeared to be less than one ventilator and less than one ICU bed per 100,000 people in Africa compared with up to thirty times that number in the USA before the pandemic, although there is regional variation. The availability of PPE across Africa was also a challenge in the early stages of the pandemic putting healthcare professionals at risk. However, this is changing with increased local production of PPE, new local designs for face masks and ventilators, as well as improved procurement processes enhanced by the recent launch of the pan-African medical supplies platform.

21Most challenging though is over-crowding and lack of running water (and therefore a lack of hand washing) among the population, with an estimated 34% to 36% of people in Africa having no access to basic household washing facilities and 30% having only limited access. This is a particular concern among refugees, who require additional efforts to help prevent the spread of the virus including education on the rationale behind lockdown activities where pertinent.

22Given these multiple issues and concerns, the UN Economic Commission for Africa (UNECA) initially estimated that the COVID-19 pandemic could potentially lead to 300,000 deaths across Africa and push 29 million people into extreme poverty. In mid-April, the WHO warned that there could be up to 10 million cases of COVID-19 in Africa within six months, rising to between 29 million and 44 million in the first year, with up to 190,000 deaths if containment measures failed. By the end of June 2020, there were over 303,000 COVID-19 cases among the WHO African countries with over 6000 deaths giving a CFR of 2.02%. Consequently, absolute numbers of COVID-19 related deaths to date are still lower in Africa compared with other continents including the Americas and Europe; however, this is changing as prevalence rates rise. There are also concerns with the reliability of the data among some of the African countries due to limited detection capacity and reliable tests as well as under-reporting of both deaths and prevalence rates. For instance, there has been no official data released from Tanzania since 8 May with the President stating the pandemic has largely been defeated despite concerns with truck drivers testing positive at borders and continued ongoing concerns with under-reporting. Having said this, there have been concerns with the reliability of testing equipment.

23Other potential factors for currently lower prevalence rates and deaths in Africa compared with other continents could be a comparatively younger population as well as rapid instigation of lockdown and other measures. which build on experiences with other infectious diseases aided by the African Union, WHO Africa and the African Centre for Disease Control (CDC), as well as sensitivity of the virus to ambient temperatures. The African CDC has been actively coordinating a strong multilateral response amongst African governments and other stakeholders towards COVID-19 building on the activities by the WHO in Africa and others. The establishment of National Public Health Institutes among many African countries has also improved the response to public health threats. Activities across Africa include developing laboratory expertise, training a volunteer health workforce, and risk communication. As mentioned, these built on Africa´s experience in dealing with other infectious diseases including Ebola, HIV, malaria and TB. The United Nations has also established a knowledge hub for COVID-19 to help African countries learn from each other. Testing has also appreciably increased in recent weeks across Africa helped by Africa CDC and the WHO Africa, who have provided testing kits and training, with 48 African countries able to test for COVID-19 by 29 April 2020 compared with just two countries at the start of the pandemic.

24Most African countries also rapidly instigated lockdown measures as well as social distancing to reduce the spread of the virus. Similar to several African countries, Ghana early on began testing travellers on arrival in the country and isolating positive cases, as well as instigating testing among its citizens. Overall, Ghana has one of the highest testing rates in Africa having performed between 110,000 and 120,000 tests by the end of April 2020. The Government of Ghana also established five key objectives to reduce the spread of the virus. Similar to most African countries, South Africa declared a national state of disaster in terms of section 27 (2) of the Disaster Management Act, 2002, and implemented a phased approach to lockdown with stage 5 introduced on March 27 2020, easing to stage 4 with effect from May 1 2020, which remains in place. Lockdown measures have now been eased among several countries following concerns about the economic and other issues including the potential for increased violence, whilst still maintaining an active response should the need arise. However, this situation is being actively monitored in case of a spike in prevalence rates.

25Medicine shortages are an increasing concern across countries and are a particular issue in Africa where typically up to 94% of its medicines are imported, and supply issues can be exacerbated in countries with ongoing conflicts. However, African countries are already taking steps to address concerns with shortages before and during the pandemic including suggesting potential alternatives. There are also ongoing programmes to address the quality of medicines across Africa. The potential for substandard and falsified medications is exacerbated when prices appreciably increase and shortages occur following endorsement of potential treatments for COVID-19 in the media. Government activities are likely to accelerate with the launch of the Lomé initiative placing falsified and substandard medicines on the highest political agenda with ongoing measures to strengthen the legal response to these medicines.

26COVID-19 has accelerated discussions on local pharmaceutical production in Africa with, for instance, the East African Community States seeking to support local production of essential medical products and supplies. Products include masks, sanitizers and ventilators, to address shortages in the region. In addition, several local companies have come forward to produce medical equipment and other products to manage the pandemic, and this will continue. This is in line with the philosophy to develop regional hubs involving several African countries to address issues of economies of scale.

Rationale Behind the Paper and the Objective

27Given the multiple issues and challenges facing African countries, we believe there is an urgent need to consolidate knowledge of ongoing activities across Africa to address the COVID-19 pandemic and to understand its impact. Similarly, there is a need to evaluate the impact of re-directing activities away from the care of patients in other priority disease areas in Africa towards COVID-19 activities given the likely consequences on increased morbidity and mortality alongside the economic and social impact.

28We are aware that several regional financial institutions, including the African Development Bank and the African Export-Import Bank, have announced significant financial support for this purpose. The commitments of the World Bank and the International Monetary Fund also provide additional mechanisms, including suspending debts, to free resources towards the COVID-19 response. These measures should help address existing concerns regarding the financial impact of government measures including lockdown measures on the livelihoods of African citizens, with many currently working in the informal sector.

29Containing the spread and impact of COVID-19, including the substantial economic impact, will though require a multipronged approach and co-operation among all key stakeholder groups going forward, including patients, with countries learning from each other. Ongoing activities include addressing the considerable misinformation about COVID-19 and potential treatments including vaccines and herbal medicines. The current controversies surrounding chloroquine/ hydroxychloroquine is just one example. As a result, there is a recognized need for scientific integrity and credibility when developing and discussing possible treatments for COVID-19 in line with recommendations from the Council for International Organizations for Medical Services. This is to ensure future public and physician trust in treatment recommendations, which forms an integral part of effectively dealing with COVID-19.

30We are aware that early in the pandemic, Africa CDC, as well as WHO Africa and their partners, spearheaded efforts to train and sensitize African governments on the need to effectively counter and reduce the levels of misinformation. Their activities included training on risk communication and regular briefings to heads of state as well as relevant sectors of government. Additional efforts have also been provided by groups such as the International Alliance of Patients' Organizations (IAPO), which have developed resource hubs to provide reliable and updated information to mitigate against misinformation and promote preventative activities.

31Education among patients can also help reduce any stigma associated with COVID-19 for recovering patients and their families as well as any mistrust by the people in their governments. We know that countries and governments have the potential to learn from the evidence base of HIV-related stigma interventions to help address such issues, as well as previous pandemics as seen with Vietnam. Potential activities among patients and their organizations include active discussions around how stigma affects different communities, reflections on personal biases, and the instigation of institutional support programmes. This is important as the COVID-19 pandemic has already provoked stigmatisation and discriminatory behaviors against people of certain ethnic backgrounds as well as anyone perceived to have been in contact with or recovered from the virus. Having said this, we have seen reasonable knowledge, attitudes and practices towards most aspects of COVID-19 among the public in China, Nepal, Pakistan and Paraguay although still room for improvement. Surveys in the UK and US have also shown that participants generally had good knowledge about the main means of transmission and the common symptoms of COVID-19. In Cameroon, the population is also aware of the disease and preventive measures. Further research is ongoing regarding why some people fail to adhere to suggested preventative measures, and we will be monitoring this.

32Consequently, the objective of this paper is to summarise and consolidate our knowledge of current activities across Africa related to COVID-19 to help provide future guidance to all key stakeholder groups. This includes following up on clinical trial activities across Africa since an early concern was that few clinical trials were being conducted across Africa. This is beginning to change, building on examples in Burkina Faso, Kenya, Nigeria, South Africa and the WHO Solidarity Trial across several African countries. By doing so, we believe we can support African countries' efforts to continue to work together to tackle the pandemic, including jointly pursuing loan waivers to help protect against the financial consequences of COVID-19.

33This will be the first paper in this series as more information and findings become available. This builds on a recent systematic review regarding the importance of viral diseases in Africa, and the fact that different approaches will be needed across Africa to tackle COVID-19, depending on current circumstances.

Methodology

34We adopted a mixed methods approach. This initially involved conducting a narrative review of the published literature as well as papers awaiting publication and internet references known to the co-authors. We did not perform a systematic review. We were aware that some systematic reviews have already been conducted and published in this area including potential treatments despite the lack of data from robust clinical trials. A number of the publications surrounding COVID-19 are also currently only available in pre-publication form and not peer-reviewed. Alongside this, much of the information regarding ongoing activities across Africa are from internet sources, and it is too early to assess the impact of these, especially as COVID-19 cases appeared later in Africa than in either China or Europe.

35We also did not systematically review each paper for its quality using well-known scales such as the Newcastle-Ottawa scale or the Cochrane risk of bias tool as our emphasis was on contextualizing the findings rather than performing a systematic review. However, the publications and internet sources were filtered by the co-authors to add robustness to the present paper and its suggestions.

36In view of this, and to provide direction for the future, we supplemented information from the literature and internet sources with additional current information from co-authors across Africa. The co-authors include senior level personnel from governments and their advisers, lecturers and researchers from academia, and clinicians, as well as those involved with activities to enhance the rational use of medicine, undertake Health Technology Assessment (HTA), document medicine shortages, and involved with patient organizations from across Africa and wider. The co-authors were asked to provide information on the following themes or topics, where known, in their own country to supplement the ongoing literature:

37Details about the current epidemiology of COVID-19 including CFRs, national responses to date and an assessment of the effectiveness, if known

38The socio-economic impact as well as the impact on healthcare delivery in other priority disease areas including medicine and equipment shortages as well as attendance at clinics. This includes any information on the unintended consequences of COVID-19 in other disease areas if known

39How issues such as medicine shortages are being addressed and the implications for local manufacturing in the future

40Current medicines and other approaches to treating patients with COVID-19 as well as ongoing studies that address issues such as false claims and hopes. In addition, ongoing activities to address falsified and sub-standard medicines

41Key lessons for the future for all key stakeholder groups

42The same questions were asked of each co-author, with country-specific replies typically consolidated where there were multiple authors in a country. The information was subsequently consolidated by two of the authors (OO and BG) and checked with each co-author during manuscript preparation to add robustness to the findings and suggestions.

43We also documented ongoing technology innovations across Africa, which we believe is important as Africa seeks to become self-sufficient in the management of patients with COVID-19 and beyond.

44Documented prevalence and mortality rates will typically be based on WHO date for consistency and reliability as there have been challenges with generating up-to-date data among a number of African countries due to the availability of testing facilities and testing kits, as well as concerns with some testing kits; however, as mentioned, this is now being addressed with the help of the WHO and others.

45The African countries chosen reflect a wide range of geographies and population sizes. We did not divide them into low- or middle-income countries as COVID-19 is likely to affect all African countries and they can learn from each other.

46Statistical analysis of the different measures and initiatives and their possible impact on the epidemiology, morbidity and mortality rates, has not been undertaken as this is too early given rising prevalence rates across Africa. In addition, our principal aim was to provide a comprehensive analysis of the current situation across Africa, including the potential implications for other infectious and non-infectious disease areas within the African continent, to stimulate ongoing debates regarding potential future activities. This is important across Africa with high prevalence rates for both infectious and non-infectious diseases, We have successfully used this dual approach in previous publications to stimulate debate in important healthcare areas and situations to provide future guidance as countries seek to improve the quality and efficiency of their approaches to medicine use, including during pandemics.

Findings

47The findings and activities are divided into sections to meet the study objectives. These include documenting the epidemiology among a range of African countries principally based on epidemiology data provided by the WHO. The aforementioned precedes discussing ongoing strategies to limit the spread of COVID-19 as well as their subsequent impact on morbidity and mortality in populations across Africa.

48The impact of COVID-19, including the unintended consequences on the healthcare system and patients, along with financial and socioeconomic issues, will be explored before documenting the subsequent impact on increased local production of pharmaceuticals and other supplies as well as any ongoing clinical studies and innovations across Africa aiming at improving future care. Finally, potential ways forward will be debated among all key stakeholder groups based on the experiences of the co-authors to provide future guidance. This includes key issues of shortages, unintended consequences, and misinformation as well as the role of patients and patient organizations in preventative measures and other interventions.

Epidemiology

49There is considerable variation in the number of recorded cases, deaths and CFRs across Africa following the first reported case on February 14, 2020, with some countries yet to record their first deaths due to COVID-19 and some countries recording only a few deaths to date ( Table 1 ), potentially reflecting different approaches and circumstances ( Tables 2 and 2A ). Table 1A in the Data Sheet gives further details of the epidemiology over time as well as recovered cases where known and documented.

Ongoing Activities to Address COVID-19 and Their Impact

50Different activities are ongoing across Africa to try and limit the impact of COVID-19. These are summarised in Table 2, with Table 2A in the Data Sheet giving additional details for those interested. As seen, prevention and treatment approaches remain broadly similar among the African countries, with a number of African countries combining approaches to provide joint guidance and updates on suggested activities, such as the East African Community. There are concerns though with limited activity in some countries, e.g., Tanzania, as well as fears that if lockdown measures are released too early due to financial and resource issues for citizens and governments these will appreciably enhance future prevalence rates.

Health and Social Impact of COVID-19 Including Impact on Other Diseases

51Measures to limit the spread of COVID-19 are having a considerable impact on other disease areas including both infectious and non-infectious diseases. Table 3 contains details of the considerable healthcare and financial impact of COVID-19 as well as ongoing activities among African countries to address these. We will be examining unintended consequences in more detail in future research projects. Similarly, there are considerable financial and socioeconomic consequences which are also being addressed, with countries having the opportunity to learn from each other.

Shortages of Medicines and Activities to Address This

52There are shortages of medicines across Africa as most medicines are imported ( Table 3A ). We are likely to see local production increasing as part of future strategies to address ongoing shortages as a result of COVID-19, and we will be monitoring this in the future.

53Table 3A in the Data Sheet contains details of ongoing shortages across Africa with countries starting to implement robust strategies to help deal with these in the future.

Clinical Trial Activities

54As mentioned, there has been limited clinical trial activity across Africa compared with higher income countries; however, this is beginning to change:

55In Botswana, there are currently no on-going clinical trials on COVID-19; however, the University of Botswana (a government-funded institution) has called for proposals on COVID-19 research, which was open until May 15, 2020.

56Egypt appears to be undertaking several clinical trials with currently 14 registered clinical trials granted expedited approval by review boards utilizing different medicines and treatment modalities.

57Currently there are no known clinical trials commissioned in Eswatini with no demonstrable commitment to commissioning COVID-19- related clinical research activities given the current pressure on resources.

58In Ghana, there currently appears to be no clinical trial research activities related to COVID-19. However, some medicinal plants with potential antiviral activity have been identified and submitted to the Centre for Scientific Research into Plant Medicine and Noguchi Memorial Institute for Medical Research for the commencement of studies/screening on their potential therapeutic anti-COVID-19/SARS-CoV-2 activities.

59Kenya is currently involved in WHO clinical trials for three medicines used in combating COVID-19. A vaccine clinical trial is envisaged in the next two or three months at the Kilifi KEMRI/Welcome Trust collaborating research site. The Institutional Review Boards have established electronic systems for protocol submissions and review feedback and expediting the review process (3-4 days for first response) to facilitate implementation.

60Three clinical trials have been registered in Nigeria but currently none have started recruiting. However, Nigeria has been included in the WHO SOLIDARITY trial with five treatment centres participating.

61A number of clinical trials are currently ongoing in South Africa for both pharmaceutical and non-pharmaceutical interventions with the Institutional Review Boards in South Africa having established electronic systems and expediting the review process to facilitate these. This includes the SOLIDARITY WHO trial with the South African research team being led by senior academics and clinicians from eight medical schools as well as the BCG vaccination trial programme for healthcare workers and the South African Ox1Cov-19 Vaccine VIDA-Trial, the first clinical trial for a vaccine against Covid-19 in South Africa with the first patients enrolled the week of June 23, 2020.

62Zimbabwe is also involved in the WHO SOLIDARITY Trial.

Technical Innovations Regarding COVID-19 From Across Africa

63There are many ongoing innovations across Africa to tackle COVID-19, and these are expected to continue. In Senegal, the Institut Pasteur, with support from the WHO, developed a US$1 COVID-19 Rapid Testing Kit to enable the country to undertake considerable testing with the government currently seeking approval for their kits to be used in other African countries. Scientists and industry partners in Ghana have also developed a test for COVID-19, a finger-prick blood test to rapidly detect antibodies, which is seen as beneficial among asymptomatic cases to reduce the spread.

64Students at the Jomo Kenyatta University of Agriculture and Technology in Kenya developed a Mobile app to help with contact tracing, triaging and case management of COVID-19 patients, with other students in Kenya also developing and making ventilators to address shortages. A multidisciplinary team at Wits University in South Africa used their design and engineering skills to create face shields. A multi-disciplinary team from Honoris United Universities from across Africa, including doctors, engineers, and students, have developed a prototype for a new non-invasive respirator alongside face shields and splash protection masks, which can be quickly and affordably manufactured via 3D printing to address current shortages.

65Scientists in Uganda have also developed hands-free hand sanitisers and rapid testing kits with a team at Makerere University involved in manufacturing low-cost ventilators to bolster the country's capacity in case demand increases.

66The Gauteng Department of Health in South Africa has introduced an app (Mpilo) based platform that supports improved service delivery and improved patient experiences in Gauteng Health facilities. The University of Pretoria in South Africa has also produced an interactive app with real-time data on COVID-19 infections to help with management. The governments in Egypt and Ghana have also recently launched apps to help with tracing people who have come into contact with COVID-19 positive patients as well as provide advice on management.

67Scientists in Ghana have also successfully sequenced the genomes of SARS-COV-2 from 15 of the samples obtained from confirmed COVID-19 cases through active collaboration using the Next Generation Sequencing (NGS) Core and High-Performance Computing system. Whilst there have been some differences in the strains between countries, all 15 genomes typically resembled (>92% similarity) the original strain isolated from China. Scientists from the Nigerian Centre for Disease Control (NCDC) and others from across Nigeria, including from Lagos University Teaching Hospital, have also reported sequencing of the SARS-CoV-2 from the first confirmed case of COVID-19 in Nigeria.

Key Lessons Among Individual African Countries and Implications for the Future for Key Stakeholder Groups

68Tabel 4A ( Data Sheet ) summarises key lessons learnt among a number of African countries going forward in the management of COVID-19 and other disease areas based on their experiences.

69Boxes 1 – 6 consolidate potential activities that could be undertaken across Africa to improve the future care of patients with COVID-19 building on existing activities ( Tables 2 and 2A ). However, we need to be mindful of a range of healthcare issues including the unintended consequences on both health and socioeconomic circumstances. This builds on Table 3, as well as Tables 3A and 4A, for individual African countries combined with recommendations for all key stakeholder groups in Africa going forward in the management of both infectious and non-infectious diseases as well as clinical and economic issues surrounding fixed dose combinations.

70Leadership and Governance

71Instigation of national/ regional pandemic planning. This includes the need for active surveillance with appropriate personnel and facilities as well as ensuring necessary healthcare workforce and structures including adequate supplies of PPE and other necessary equipment, and communication including all key stakeholder groups with reserved funds for such health emergencies. In addition, a phased approach to easing restrictions when pertinent. Such activities have worked well across countries

72Development and implementation of occupational health and safety protocols, policies and legislative frameworks taking cognisance of the risks and mechanisms of COVID-19 infection. Such protocols, policies and legislative frameworks should be consistent with national and international workplace safety policies and guidelines. Effective enforcement and monitoring mechanisms should be put in place

73Planning should take account of the impact of COVID-19 on the mental health of patients and healthcare professionals as well as other priority disease areas and potential ways to address these. This requires a sound understanding of investment/ priority decision making and activities including HTA EBM principles

74Actively plan for misinformation building on the considerable levels of misinformation already seen by end June 2020

75Good communication and financial planning are vital to address concerns with any lockdown/ curfew measures especially in countries with high levels of informal sector workers/ high level of workers dependent on a daily wage for their survival

76Lead the development of care guidelines nationally as well as take part in the development of any Pan-African care guidelines. This builds on HTA/ EBM approaches

77Ensure longer term that all healthcare professionals have the necessary training to improve the management of patients with infectious diseases as well as likely co-morbidities especially among African patients. This includes instigating antimicrobial stewardship programmes as well as Infection Prevention Control groups in hospitals where these do not currently exist

78Enhance collaboration between African countries, especially those with shared borders. This builds on ongoing collaborations including the East African Community with their shared plans to tackle COVID-19

79Explore telemedicine and other similar approaches to help with diagnosis of infectious diseases and address unintended consequences especially in patients with chronic NCDs as a consequence of any lockdown, alongside investigating the potential of robots for care delivery

80Continue with measures to reduce the extent of falsified and sub-standard medicines within Africa as well as measures to address concerns with misinformation. Alongside this, seek ways to enhance local/ regional production of medicines, PPE and other equipment to reduce reliance on imports

81Health Care Workforce (HCW)

82Strengthen health care systems including ambulatory care systems as well as policies and initiatives to improve identification and management of COVID-19, as well as other high priority disease areas (capacity building)

83Instigate practices to ensure that essential health services offered by the private healthcare sector are not compromised

84Seek to address shortages of physicians where applicable including training and utilising of other healthcare professionals. This can include task shifting including a greater role for other professionals such as pharmacists ( Box 4 ). As part of this, develop medium to long term epidemic/pandemic training for healthcare personnel to improve their preparedness and capacities for such health emergencies

85Enhance the professionalism of HCWs including initiatives to reduce inappropriate prescribing of antimicrobials where this occurs

86Strengthen community systems through capacity building of community owned resources including community extension health workers as well as voluntary healthcare workers as these are typically the first point of contact in communities

87Ensure HCWs continue to have access to PPE as well as additional training (where relevant) in dealing with pandemics as the safety of HCWs and patients is critical during pandemics

88Seek to share basic best practices across countries, including what works well in COVID-19 case management, infection, prevention and control.

89Financing/Socioeconomic issues

90As most African currently countries rely on foreign input, governments need to find alternative sources of income in the future through agriculture and technology advances building on current innovations

91Minimize the socioeconomic impact through enhancing national solidarity and prioritization of social cohesion.

92Seek to protect vulnerable populations including the benefits and privileges of low-wage workers as well as address access to healthcare and support for all to reduce the burden that makes vulnerable people less able to follow public health directives

93Make it possible for small-scale business to survive periods of economic downturns occasioned by public health crisis. This can include facilitating the disbursement of interest loans to SMEs as well as reward local companies in the country with tax incentives/guaranteed bank loans to enable them recover post COVID-19

94Research Including Unintended Consequences for Both Infectious Diseases (including AMR) and non-infectious diseases

95Promote and fund operational/national research on the impact of COVID-19 on infectious diseases (including AMR) and non-infectious diseases especially the unintended consequences ( Table 3 ). This is particularly important in Africa where national programmes are just starting to address AMR as well as NCDs including CVD, diabetes, and mental health

96Continue to promote research into potential risk factors for morbidity and mortality among African patients given the differences that can exist between patients in Africa and those in high income countries

97Continue with research programmes aimed at mitigating against infectious diseases (including AMR) and non-infectious diseases across countries to add to the debate about the potential impact of unintended consequences

98Instigate research into new ways to manage patients with both infectious diseases and NCDs where there are constraints on patient access including better use of new technologies including telemedicine and consultations through the internet/ mobile telephones

99NB: AMR, Antimicrobial Rsistance; CVD, Coronary Vascular Disease; EBM, Evidence-base medicine; HTA, Health Technology Assessment; NCDs, Non-communicable diseases; PPE, Personal Protective Equipment; SME, Small and Medium size enterprise.

100Short Term

101Continue reviewing emerging medicines that could be used in the management of COVID-19 to inform and update clinical protocols

102Disseminate findings via Ministry of Health and other websites to address current levels of misinformation

103Continue to undertake research for evidence-based interventions given the current controversies surrounding a number of suggested treatments for COVID-19, and encourage greater collaboration between governments, healthcare professionals and patient organizations researching and disseminating the findings

104Strengthen HTA capabilities especially when Ministries of Health are confronted with different potential interventions to address COVID-19 coupled with limited resources. This builds on existing initiatives across Africa including Ghana, Kenya and South Africa as well as the recent cost-benefit analysis on social distancing in Ghana and ICU versus care in general wards for patients with severe COVID-19

105As part of this, upgrade research into priority decision making especially given the many competing healthcare needs among patients in Africa including those with infectious and non-infectious diseases as well as co-morbidities

106Longer Term

107Seek to invest in personnel and resources to enhance HTA/ EBM capabilities within countries where currently limited personnel and resources to enable greater critique of evidence based alternatives

108Seek to establish HTA collaborations across African countries to avoid duplication building on experiences in Europe

109NB: EBM, Evidence-base medicine; HTA, Health Technology Assessment.; ICU, intensive care unit.

110Short Term

111Deployment of higher number of physicians where possible to help deal with the pandemic as well as other priority disease areas. Ensure physicians are motivated emotionally, mentally and financially to help deal with the pandemic especially given the likely impact of the virus on their mental health. Educational interventions and psychological support will be needed to ensure greater understanding of COVID-19 and its implications including better coping strategies. Psychological support could include development of support systems among all stakeholders and the general community.

112Physicians need to be provided with adequate PPE and training to address current fears, with hospitals provided with adequate logistical support (PPE, ventilators, medication, non-consumables)

113Embrace alternative ways of working including devolved responsibilities as well as the use of new technologies that help improve the care of all patients during pandemics

114Introduce greater opportunities for the training and re-training of ambulatory care physicians in the management of patients with COVID-19 and any co-morbidities given the challenges that can exist with differential diagnosis. As part of this, push for the instigation of antimicrobial stewardship programmes as well as IPC groups in hospitals where these do not currently exist

115Work with others to address concerns with misinformation as well as falsified and sub-standard medicines. In addition, concerns with potential shortages of medicines and equipment and alternative approaches

116Longer Term

117Building on current experiences and collaborations on the best way to treat patients with COVID-19 and the aftermath including concerns with mental health disorders

118Focus on training of sufficient physicians from non-public health or circulatory medicine specialities to ensure a higher number of staff with transferable skills relevant to a pandemic that can be rapidly re-deployed

119There is an urgent need generally to employ more health personnel to augment current inadequacies across Africa. This includes exploring measures to attain and retain physicians

120NB: IPC, Infection, prevention and control; PPE, Personal Protective Equipment.

121Short Term

122Seek ways to ensure that medicines, or suitable alternatives, that are deemed helpful to patients with COVID-19 are routinely available coupled with medicines for other priority disease areas

123Work with Government agencies when falsified or sub-standard medicines are suspected to reduce their supply

124In hospitals, seek to ensure that hospital pharmacists are part of COVID-19 treatment teams including ASPs and IPC teams. This means that hospital pharmacist must keep abreast on current treatment research and protocols for COVID-19 and be familiar with EBM techniques given ongoing controversies. In addition, should be provided with any necessary PPE including face shields and googles

125Hospital pharmacists should be involved in educating patients/staff on COVID-19 management especially on non-pharmacological and pharmacological interventions

126Where appropriate, pharmacist should be encouraged to prepare cost-effective WHO-recommended hand sanitizers for their facilities

127In the community, pharmacists have a vital role as they are often the first healthcare professional that patients contact regarding respiratory/ influenza diseases especially in countries with high patient co-payments, concerns with access to ambulatory healthcare facilities as well as issues of affordability to pay for a physician and their medicines. This includes encouraging self care/ hygiene measures including the supplying and wearing of masks and the need for regular hand washing as well as trying to protect patients against stock-outs of pertinent medicines

128Community pharmacists can also discuss appropriate treatments including arguing against the need for antibiotics where this is a concern and encouraging appropriate referral where possible

129Community pharmacists and others can also push for extended supply of medicines where appropriate as well as help engage in discussions regarding adherence to medicines using different technologies especially given ongoing concerns with adherence to medicines without regular input from pharmacists and other professionals.

130Pharmacists can also suggest alternative approaches during times of medicine shortages including potential OTC treatments.

131They can also help improve stock controls to reduce potential shortages of key medicines with associated price increases, which is important in LMICs with high patient co-payments.

132Community pharmacists can also be involved in vaccination programmes given current concerns, as well as help administer a vaccine for COVID-19 when available with research suggesting that when pharmacists provide immunizations, they substantially increase the number of vaccinated people in the community

133Longer Term

134Increase the training of Pharmacists at both hospital and community levels to be prepared/actively involved in management of COVID-19 patients as well as addressing unintended consequences including the use of technology to address issues with adherence

135Pharmacists should be part of appropriate relevant training and the development of emergency plans and workflows to deal with future pandemics and their consequences

136NB: ASPs, Antimicrobial Stewardship Programmes; EBM, Evidence-based medicine; IPC, Infection, Prevention and Control; PPE, Personal protective equipment.

137Short Term

138Work with other professionals to identify optimal methods to deal with the care of patients with COVID-19 both in hospitals and in the community

139This includes making sure that healthcare professionals have the necessary PPE and equipment to deal with COVID-19 patients

140Seek to instigate training regarding the proper donning and removal of PPE during routine duties and in the management of suspected/positive COVID-19 cases if not in place

141Be part of ongoing plans to help improve the management of high priority disease areas outside of COVID-19 to make sure these patients are not neglected

142Work with necessary professionals to ensure the mental health of healthcare professionals and patients is not neglected during and post the pandemic. This includes helping to address issues of stigma

143Longer Term

144Be part of elaborate plans to improve the management of patients with COVID-19 and other priority disease areas including re-distribution of activities to address shortages with physicians and other HCPs

145Seek to work with universities, companies and other groups to develop in-house/ in-country technologies to treat COVID-19 patients and be less reliant on imports in the future

146NB: HCPs, Healthcare Professionals; PPE, Personal protective equipment.

147Short Term

148Mobilize and engage with traditional, cultural, and other leaders who are respected and listened to in their communities to disseminate important health messages including hygiene and social distance measures associated with COVID-19 to help address current low levels of health literacy in a number of African countries. This includes addressing current misconceptions about the importance of using face masks, and how to use them appropriately, as many patients do not appreciate the need as well as helping acknowledge that some people with respiratory problems may have difficulties using masks for long, which needs to be effectively tackled

149Engage with various channels to help reassure COVID-19 patients that they pose no threat to the community after treatment, and should continue with their lives, as well as help address issues of stigma and discrimination against COVID-19 patients when these arise

150Work with government bodies to help address issues of misinformation about vaccines and treatments including misconceptions about vaccines and the consequences. In addition, work with all key stakeholder groups to help address the mental health issues that will arise from the current pandemic

151Patients organizations should work with regulatory authorities and professionals generally to strengthen ethical conduct and professionalism post the pandemic including promoting only evidence-based approaches across social and other media given concerns with the level of misinformation during the pandemic

152Recovered COVID-19 patients can be used as ambassadors to sensitise the populace about the reality of the pandemic, and the need to avoid stigmatization

153Social media has proved useful and can provide an efficient means for patients and patient organizations to effectively communicate with their communities. However, this needs to be carefully managed to reduce the level of any misinformation and subsequent adverse consequences. This builds on activities with traditional, cultural, and other leaders

154Empower patients on medication safety and polypharmacy concerns as well as educate patients about self-management generally of their conditions especially patients with chronic NCDs in the absence of routine clinics

155Help explore possible telemedicine approaches to reduce reliance on clinic attendance, which in itself can be problematic outside of the pandemic if this involves extensive travel and waiting times

156Longer Term

157Seek to develop patient-level data bases to routinely collect data on patients to help with future planning and care delivery

158Enhance the role of patient organizations within countries where pertinent as they can play a long-term role regarding advocacy and the spreading of information not only on COVID-19 but also other diseases and concerns. Patient organizations also have a key role generally to encourage changes in behaviors that promote good underlying health to support health outcomes and reduce the risk of severe symptomatic responses to a pandemic

159A key area will be patients especially in view of their necessary compliance with any lockdown and social distancing activities as well as considerations for the unintended consequences of COVID-19. These include mental health considerations, managing maternal and childbirth challenges, the identification and management of other NCDs as well as other infectious diseases.

160HTA will also be a crucial area especially given concerns with the extent of misinformation regarding COVID-19 and the implications. In addition, the need for governments to prioritise their limited resources across disease areas, rather than devoting appreciable personnel and resources to one area to the detriment of others as seen currently with activities regarding COVID-19 ( Tables 2, 2A, and 3 ). However, there are challenges including available personnel and resources as well as typically a greater focus on medicines among HTA units rather than other technologies. This is changing with studies in Ghana evaluating the cost-benefit of moderate social distancing policies and the cost-effectiveness of different prevention measures ( as well as groups in South Africa HTA evaluating the cost-effectiveness of ICU versus care on general wards with patients with severe COVID-19.

161HTA and EBM will also be important in the development of clinical guidelines for Africa considering the costs involved with developing de-novo guidelines. Africa could certainly gain from a Pan-African guideline for the management of COVID-19 as knowledge grows to provide scientifically-based recommendations, similar to initiatives for NCDs. Global evidence communities including the BMJ under its Best Practice series are already adopting this approach for knowledge generation, synthesis, and translation to facilitate evidence-based decisions, and any Pan-African initiatives should build on this. Groups such as IAPO are also important with their resource hubs to provide robust, reliable, and updated information to help improve the care of patients. In the meantime, we are beginning to see African countries taking steps to reduce the level of misinformation and this is likely to grow.

Discussion and Next Steps

162We believe this is the first study to comprehensively document ongoing activities throughout Africa to tackle the health, financial and socioeconomic consequences of COVID-19. This is important given the high prevalence of both infectious and non-infectious diseases in Africa, the high number of people at or below the poverty level compared with other continents and higher income countries, as well as concerns with the lack of personnel, hospital beds and equipment.

163There have been different activities across Africa to prevent the spread of COVID-19 and reduce mortality rates ( Tables 2 and 2A ). African countries have broadly followed similar multiple approaches in terms of prevention including closing borders and instigating lockdown measures including travel restrictions, social distancing and testing. Closure of borders and quarantining along with other public health measures appear successful in reducing the spread of the virus, and this certainly appears to be the case among a number of the African countries. Encouragingly, to date there have been no or very few reported deaths among some of the African countries ( Tables 1 and 1A ), mirroring for instance the situation in other LMICs including Vietnam. Encouragingly as well, there have been a number of innovations coming from the African continent to help with identification and management of patients with COVID-19, which includes local production of hygiene equipment as well as low-cost ventilators (Section 3.6). Alongside this, initiatives to enhance the production of medicines in Africa to reduce their reliance on imported medicines and other essential supplies. This bodes well with dealing with future pandemics in Africa. We will continue though to monitor prevalence and mortality rates across Africa as well as potential reasons for the limited mortality up to late June 2020, certainly when compared with a number of European countries and the USA, including potential issues around ethnicity and other factors.

164However, extensive lockdown and other measures to help control the spread of the virus have been at a cost including the negative impact on other disease areas as well as financial and socioeconomic consequences ( Table 3 ). This includes an increase in mental health disorders exacerbated by issues of stigma. Table 3 shows clearly the need to strengthen or enhance existing healthcare infrastructures in many countries to respond to such pandemics and indeed promote better population health and underlying lifestyle behaviors. While good health system infrastructure does not guarantee better health outcomes it increases the opportunities for these to happen.

165Groups such as IAPO are important to reduce any stigma associated with COVID-19. In the process of stigmatisation, people are being labelled, stereotyped, separated, and/or experience loss of status and discrimination because of a potential negative affiliation with the disease. Stigma can drive people to hide their illness to avoid discrimination, which potentially prevents them from promptly seeking help, and could discourage them from adopting healthy behaviors, which is concerning. This is because such barriers could potentially contribute to more severe health problems, ongoing transmission, and difficulties with controlling infectious diseases. As a result, there are ongoing strategies to address these challenges including a greater role for patient organizations.

166There are real concerns though if lockdown policies are eased too early due to financial and socioeconomic pressures, and we will be following this up in future research projects. We will also be following up the unintended consequences of COVID-19 on other infectious and non-infectious disease areas as well as vaccination programmes. In the meantime, Boxes 1 – 6 provide direction to African countries going forward as they start to ease their lockdown restrictions and address the unintended consequences of the pandemic.

Limitations

167We are aware that we have not undertaken a systematic review. This is because, as mentioned, a number of quoted papers have not been formally peer-reviewed and a great deal of information regarding country activities is currently only available on the internet. In addition, cases of COVID-19 started later in Africa than in China and Europe, and it is too early to formally assess the impact of polices. A number of clinical trials regarding possible treatments for COVID-19 have also only recently started.

168However, we believe the strength of our paper lies in its comprehensive approach including ongoing and planned activities from across Africa and next steps from senior level personnel, which we will be building upon as more data becomes available. This includes activities against COVID-19 and future activities to re-balance the care of patients with other infectious diseases as well as NCDs.

Conclusion

169There have been multiple activities across Africa to try and reduce the spread of COVID-19 with its subsequent impact on morbidity and mortality with the help of international and national groups including the WHO and African CDC. This is despite concerns with available resources, personnel and equipment compared with higher income countries. To date, mortality rates appear appreciably lower than seen in a number of European countries and the USA possibly due to early lockdown and other measures including early closure of borders and quarantining of returning travellers, which is encouraging given initial concerns in Africa. However, infection rates continue to rise which is a concern especially as lockdown measures are being eased in a number of African countries. Encouragingly, multiple activities were typically introduced early across Africa building on the experiences with other infectious diseases, with countries continuing to learn from each other. However, there are a number of unintended consequences which are likely to result in increased morbidity and mortality of other infectious diseases and NCDs. Activities are ongoing to try and reduce the impact, and we will be monitoring these in the future.

Orcid Numbers

170Olayinka O. Ogunleye, orcid.org/0000-0002-8921-1909

171Debjani Mueller, orcid.org/0000-0001-7796-982X

172Nenad Miljkovic, orcid.org/0000-0003-1282-3883

173Julius C. Mwita, orcid.org/0000-0002-5947-3684

174Godfrey Mutashambara Rwegerera, orcid.org/0000-0002-5896-6065

175Bene D Anand Paramadhas, orcid.org/0000-0002-8204-1417

176Mohamed Hussein, orcid.org/0000-0003-0349-7262

177Wafaa M. Rashed, orcid.org/0000-0001-7531-2840

178Loveline Niba, orcid.org/0000-0002-5938-4913

179Melaine Nsaikila, orcid.org/0000-0003-2335-3768

180Adefolarin A. Amu, orcid.org/0000-0003-3212-2283

181Daniel Afriyie, orcid.org/0000-0001-8859-3565

182Seth K. Amponsah, orcid.org/0000-0001-7411-0972

183Israel Sefah, orcid.org/0000-0001-6963-0519

184Tebello Violet Sarele, orcid.org/0000-0002-5874-6599

185Refeletse Keabetsoe Mafisa, orcid.org/0000-0001-9713-466X

186Felix Khuluza, orcid.org/0000-0002-8334-0160

187Dan Kibuule, orcid.org/0000-0002-6908-2177

188Francis Kalemeera, orcid.org/0000-0002-4320-5087

189Mwangana Mubita, orcid.org/0000-0002-8732-8644

190Tshegofatso Maimela, orcid.org/0000-0002-8554-1329

191Joseph Fadare, orcid.org/0000-0002-5641-1402

192Johannes Hugo, orcid.org/0000-0002-9406-8801

193Ibrahim Chikowe, orcid.org/0000-0002-8231-9140

194Johanna C. Meyer, orcid.org/0000-0003-0462-5713

195Enos M. Rampamba, orcid.org/0000-0002-3492-9104

196Abubakr Alfadl, orcid.org/0000-0002-3014-1408

197Elfatih M. Malik, orcid.org/0000-0002-8071-8092

198Ombeva Malande, orcid.org/0000-0002-1840-7402

199Aubrey Kalungia, orcid.org/0000-0003-2554-1236

200Chiluba Mwila, orcid.org/0000-0003-0160-1222

201Ioana D. Olaru, orcid.org/0000-0003-3392-9257

202Trust Zaranyika, orcid.org/0000-0003-4363-7709

203Blessmore V Chaibva, orcid.org/0000-0001-7858-3814

204Nyasha Masuka, orcid.org/0000-0003-4653-8626

205Corrado Barbui, orcid.org/0000-0003-1073-9282

206Ruaraidh Hill, orcid.org/0000-0002-2801-0505

207Tomasz Bochenek, orcid.org/0000-0001-9915-7267

208Amanj Kurdi, orcid.org/0000-0001-5036-1988

209Stephen Campbell, orcid.org/0000-0002-2328-4136

210Thuy Nguyen Thi Phuong, orcid.org/0000-0001-7939-5276

211Antony P Martin, orcid.org/0000-0003-4383-6038

212Brian Godman, orcid.org/0000-0001-6539-6972

Author Contributions

213OOO, DB, JF, and BG developed the concept of the paper and undertook the initial literature review. OOO, JF, JMe, ACK, and BG developed the draft questionnaire. All authors subsequently contributed to the development of the paper including country activities as well as critiqued subsequent drafts before submission.

Conflict of Interest

214AM is employed by HCD Economics.

215The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. However, a number of them are employed by national or regional governments in Ministries of Health or are advisers to them.

References 521

1.
Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection · 2020
Corrected
2.
Abdool Karim S. S. (2020 ). The South African Response to the Pandemic. N Engl. J. Med. 382 (24), e95.
Not in our library10.1056/nejmc2014960
3.
Abena P. M. Decloedt E. H. Bottieau E. Suleman F. Adejumo P. Sam-Agudu N. A. (2020 ). Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am. J. Trop. Med. Hyg. 102 (6), 1184–1188.
Not in our library10.4269/ajtmh.20-0290
4.
Achan J. (2020 ). Dr. Wayengera: The man behind Uganda's COVID-19 testing kits. Available at: https://www.newvision.co.ug/new_vision/news/1518668/dr-misaki-wayengera-uganda-covid-19-test-kits.
Not in our library
5.
Achwoka D. Waruru A. Chen T. H. Masamaro K. Ngugi E. Kimani M. (2019 ). Noncommunicable disease burden among HIV patients in care: a national retrospective longitudinal analysis of HIV-treatment outcomes in Kenya, 2003-2013. BMC Public Health 19 (1), 372.
Not in our library10.1186/s12889-019-6716-2
6.
Acosta A. Vanegas E. P. Rovira J. Godman B. Bochenek T. (2019 ). Medicine Shortages: Gaps Between Countries and Global Perspectives. Front. Pharmacol. 10 (763).
Not in our library10.3389/fphar.2019.00763
7.
Adow M. (2020 ). COVID-19 adds to DR Congo's multiple health crises - The healthcare system in one of the world's poorest countries is struggling to treat cholera, measles, ebola - and now coronavirus. Available at: https://www.aljazeera.com/news/2020/04/covid-19-adds-dr-congos-multiple-health-crises-200413180551574.html
Not in our library
8.
Adunlin G. Murphy P. Z. Manis M. (2020 ). COVID-19: How Can Rural Community Pharmacies Respond to the Outbreak? J. Rural Health.
Not in our library10.1111/jrh.12439
9.
Adusei A. (2020 ). Covid-19 is hitting communities in Ghana hard. BMJ.
Not in our library
10.
AFP-JIJI (2020 ). Coronavirus stigma weighs heavily in sub-Saharan Africa. Available at: https://www.japantimes.co.jp/news/2020/05/20/world/social-issues-world/virus-stigma-sub-saharan-africa/#.XsYjk2hKjIU.
Not in our library
11.
Africa CDC (2020 ). Coronavirus Disease 2019 (COVID-19). Available at: https://africacdc.org/covid-19/.
Not in our library
12.
Africa Health IT News (2020 a). Minet, clinic launch telemedicine service in Kenya. Available at: http://africahealthitnews.com/minet-clinic-launch-telemedicine-service-in-kenya/.
Not in our library
13.
Africa Health IT News (2020 b). Telemedicine Technology deplore in Kenya To Enhance Fight Against Covid-19. Available at: http://africahealthitnews.com/telemedicine-technology-deplore-in-kenya-d-to-enhance-fight-against-covid-19/.
Not in our library
14.
Africa News Agency (2020 ). Malawi public transport operators raise fares to offset restrictions. Available at: https://www.iol.co.za/news/africa/malawi-public-transport-operators-raise-fares-to-offset-restrictions-45983229.
Not in our library
15.
Africa News (2020 a). HIV-positive people in SA skipping treatment over Covid-19 fears. Available at: https://www.africannewsagency.com/news-politics/HIV-positive-people-in-SA-skipping-treatment-over-Covid-19-fears-24770911.
Not in our library
16.
African Development Bank (2020 ). President Adesina discusses the immediate and long-term impact of COVID-19 in Africa. Available at: https://www.afdb.org/en/news-and-events/multimedia/video/president-adesina-discusses-immediate-and-long-term-impact-covid-19-africa-35755.
Not in our library
17.
Africa News (2020 b). Malawi coronavirus: health workers protest over risk allowance. Available at: https://www.africanews.com/2020/04/21/malawi-coronavirus-health-workers-protest-over-risk-allowance//.
Not in our library
18.
Afriyie D. K. Sefah I. A. Sneddon J. Malcom W. McKinney R. Cooper L. (2020 ). Antimicrobial Point Prevalence Surveys in two Ghanaian hospitals: opportunities for antimicrobial stewardship. JAC Antimicrob. Resist. 1–9.
Not in our library10.1093/jacamr/dlaa001
19.
Agbobli S. (2020 ). ICGC donates GHC 100K towards COVID-19 trust fund. Available at: https://www.theghanareport.com/icgc-donates-gh%E2%82%B5100k-towards-covid-19-trust-fund/.
Not in our library
20.
Agence de Presse Africaine (2020 ). Ghana Chamber of Mines donates $2m to Covid-19-Trust Fund. Available at: http://apanews.net/en/news/ghana-chamber-of-mines-donates-2m-to-covid-19-trust-fund.
Not in our library
21.
ALCED (2020 ). Time Period:02/05/2019-02/05/2020. Available at: https://acleddata.com/dashboard/#/dashboard.
Not in our library
22.
Aljazeera News (2020 a). Africa coronavirus cases could hit 10 million in six months: WHO COVID-19 cases on the continent may shoot up from thousands to millions if models are accurate, UN health agency says. Available at: https://www.aljazeera.com/news/2020/04/africa-coronavirus-cases-hit-10-million-months-200417055006127.html.
Not in our library
23.
Aljazeera News (2020 b). Tanzania president questions coronavirus kits after animal test - President Magufuli says tests were found to be faulty after goat, sheep and pawpaw samples test positive for COVID-19. Available at: https://www.aljazeera.com/news/2020/05/tanzania-president-questions-coronavirus-kits-animal-test-200503174100809.html.
Not in our library
24.
Aljazeera News (2020 c). Kenya floods kill 194 people, displace tens of thousands - Government says 100,000 people displaced following torrential rain in the western part of the country. Available at: https://www.aljazeera.com/news/2020/05/kenya-floods-kill-194-people-displace-tens-thousands-200506133348867.html.
Not in our library
25.
Aljazeera (2020 ). All you need to know about PPE. Available at: https://www.aljazeera.com/news/2020/04/ppes-important-200419071536635.html.
Not in our library
26.
All Africa (2020 ). Kenya: Denmark Gives Kenya Sh320m to Boost COVID-19 Fund. Available at: https://allafrica.com/stories/202004050111.html.
Not in our library
27.
Allen M. B. Mirsaeidi M. (2020 ). Health and Economy in COVID-19 Era: A Plan for Reconstituting Long-Term Economic Security. Front. Public Health 8 (235), 1–3.
Not in our library10.3389/fpubh.2020.00235
28.
Almeida P. Silva T. B. C. de Assis Acurcio F. Guerra Junior A. A. Araujo V. E. Diniz L. M. (2018 ). Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. Patient 11 (4), 377–389.
Not in our library10.1007/s40271-017-0291-3
29.
Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis · 2020
No notice
30.
Al-Quteimat O. M. Amer A. M. (2020 ). SARS-CoV-2 outbreak: How can pharmacists help? Res. Soc. Adm. Pharm.
Not in our library10.1016/j.sapharm.2020.03.018
31.
Amariles P. Ledezma-Morales M. Salazar-Ospina A. Hincapié-García J. A. (2020 ). How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal. Res. Soc. Adm. Pharm.
Not in our library10.1016/j.sapharm.2020.03.007
32.
Amegah A. K. (2018 ). Tackling the Growing Burden of Cardiovascular Diseases in Sub-Saharan Africa. Circulation 138 (22), 2449–2451.
Not in our library10.1161/circulationaha.118.037367
33.
Anand Paramadhas B. D. Tiroyakgosi C. Mpinda-Joseph P. Morokotso M. Matome M. Sinkala F. (2019 ). Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications. Expert Rev. Anti-Infe. Ther. 17 (7), 535–546.
Not in our library10.1080/14787210.2019.1629288
34.
COVID‐19: lambda interferon against viral load and hyperinflammation · 2020
No notice
35.
Ang L. Lee H. W. Choi J. Y. Zhang J. Soo Lee M. (2020 ). Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integr. Med. Res. 9 (2), 100407.
Not in our library10.1016/j.imr.2020.100407
36.
Anna C. (2020 ). Protest vs. Africa's 1st COVID-19 vaccine trial shows fears. Available at: https://news.yahoo.com/protest-vs-africas-1st-covid-102207018.html.
Not in our library
37.
Arhinful E. (2020 ). Pay attention to Meningitis outbreak in Upper West Region- Parliament directs Health Ministry. Available at: https://citinewsroom.com/2020/04/pay-attention-to-meningitis-outbreak-in-upper-west-region-parliament-directs-health-ministry/.
Not in our library
38.
Aruru M. Truong H. A. Clark S. (2020 ). Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Res. Soc. Adm. Pharm.
Not in our library10.1016/j.sapharm.2020.04.002
39.
Asamoah A. (2020 ). Methodist Church donated GHC 100,000 towards coronavirus fight. Available at: https://www.theghanareport.com/methodist-church-donates-ghc100000-towards-coronavirus-fight/.
Not in our library
40.
Asamoah J. K. K. Owusu M. A. Jin Z. Oduro F. T. Abidemi A. Gyasi E. O. (2020 ). Global stability and cost-effectiveness analysis of COVID-19 considering the impact of the environment: using data from Ghana. Chaos Solitions Fractals 140, 110103.
Not in our library10.1016/j.chaos.2020.110103
41.
Ashly J. (2020 ). Is Tanzania covering up the real number of coronavirus deaths? Suspicion over official COVID-19 numbers grows as critics accuse gov't of of failing to inform public on true extent. Available at: https://www.aljazeera.com/news/2020/05/tanzania-covering-real-number-coronavirus-deaths-200511054304751.html.
Not in our library
42.
Associated Press (2020 ). Refugees Protest Under Coronavirus Lockdown in Rwanda. 17 April 2020. Available at: https://www.voanews.com/covid-19-pandemic/refugees-protest-under-coronavirus-lockdown-rwanda.
Not in our library
43.
Ataguba J. E. (2020 ). COVID-19 Pandemic, a War to be Won: Understanding its Economic Implications for Africa. Appl. Health Econ. Health Policy 18 (3), 325–328.
Not in our library10.1007/s40258-020-00580-x
44.
Athumani H. (2020 ). Ugandan HIV-Positive Volunteer Goes Distance to Deliver ARVs. Available at: https://www.voanews.com/covid-19-pandemic/ugandan-hiv-positive-volunteer-goes-distance-deliver-arvs.
Not in our library
45.
Auta A. Hadi M. A. Oga E. Adewuyi E. O. Abdu-Aguye S. N. Adeloye D. (2019 ). Global access to antibiotics without prescription in community pharmacies: A systematic review and meta-analysis. J. Infection 78 (1), 8–18.
Not in our library10.1016/j.jinf.2018.07.001
46.
Bae S. Kim M. C. Kim J. Y. Cha H. H. Lim J. S. Jung J. (2020 ). Notice of Retraction: Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2. Ann. Internal Med. 173 (1), 79.
Not in our library10.7326/l20-0745
47.
Baleta A. (2020 ). COVID-19: SA to start enrolling patients in landmark WHO trial. Available at: https://www.spotlightnsp.co.za/2020/04/01/covid-19-sa-to-start-enrolling-patients-in-landmark-who-trial/
Not in our library
48.
Bambra C. Riordan R. Ford J. Matthews F. (2020 ). The COVID-19 pandemic and health inequalities. J. Epidemiol. Community Health, jech-2020–214401.
Not in our library10.1136/jech-2020-214401
49.
Basu S. (2020 ). Non-communicable disease management in vulnerable patients during Covid-19. Indian J. Med. Ethics V (2), 103–105.
Not in our library10.20529/ijme.2020.041
50.
Bates I. John C. Seegobin P. Bruno A. (2018 ). An analysis of the global pharmacy workforce capacity trends from 2006 to 2012. Hum. Resour. Health 16 (1), 3.
Not in our library10.1186/s12960-018-0267-y
51.
Bavier J. (2020 ). At least 300,000 Africans expected to die in pandemic: U.N. agency. Available at: https://www.reuters.com/article/us-health-coronavirus-africa-un/at-least-300000-africans-expected-to-die-in-pandemic-u-n-agency-idUSKBN21Z1LW.
Not in our library
52.
Beigel J. H. Tomashek K. M. Dodd L. E. Mehta A. K. Zingman B. S. Kalil A. C. (2020 ). Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl. J. Med.
Not in our library10.1056/nejmc2022236
53.
Berlin D. A. Gulick R. M. Martinez F. J. (2020 ). Severe Covid-19. N Engl. J. Med.
Not in our library10.1056/nejmcp2009575
54.
Bijlmakers L. Mueller D. Kahveci R. Chen Y. van der Wilt G. J. (2017 ). Integrate-HTA: A Low- And Middle-Income Country Perspective. Int. J. Technol. Assess. Health Care 33 (5), 599–604.
Not in our library10.1017/s0266462317000927
55.
Bissada A.-M. (2020 ). Coronavirus: 3D print of ventilators, easy and cheap to produce says lead researcher. Available at: https://www.theafricareport.com/28212/coronavirus-3d-print-of-ventilators-easy-and-cheap-to-produce-says-lead-researcher/.
Not in our library
56.
Blanco J. L. Ambrosioni J. Garcia F. Martinez E. Soriano A. Mallolas J. (2020 ). COVID-19 in patients with HIV: clinical case series. Lancet HIV 7 (5), e314–e316
Not in our library10.1016/s2352-3018(20)30111-9
57.
Bloch E. M. Shoham S. Casadevall A. Sachais B. S. Shaz B. Winters J. L. (2020 ). Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest.
Not in our library10.1172/jci138745
58.
BMJ Best Practice - Coronavirus disease 2019 (COVID-19) (2020 ). 7 May 2020. https://bestpractice.bmj.com/topics/en-gb/3000168/pdf/3000168/Coronavirus%20disease%202019%20%28COVID-19%29.pdf.
Not in our library
59.
Bochenek T. Abilova V. Alkan A. Asanin B. de Miguel Beriain I. Besovic Z. (2017 ). Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. Front. Pharmacol. 8, (942), 1–24.
Not in our library10.3389/fphar.2017.00942
60.
Bode B. Garrett V. Messler J. McFarland R. Crowe J. Booth R. (2020 ). Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J. Diabetes Sci. Technol. 14 (4), 813–821
Not in our library10.1177/1932296820924469
61.
Bokpe S. (2020 ). Watch out for counterfeit chloroquine on the market-FDA warns. Available at: https://www.theghanareport.com/fda/.
Not in our library
62.
Bonner L. (2020 ). Kenya Opens First Telemedicine Center For Covid-19 Detection. Available at: https://www.axisimagingnews.com/news/kenya-opens-first-telemedicine-center-for-covid-19-detection.
Not in our library
63.
Bonnet F. Vanek J. Chen M. (2019 ). Women and men in the informal economy: a statistical picture. Available at: https://www.ilo.org/wcmsp5/groups/public/—ed_protect/—protrav/—travail/documents/publication/wcms_711798.pdf.
Not in our library
64.
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection · 2020
No notice
65.
Boulware D. R. Pullen M. F. Bangdiwala A. S. Pastick K. A. Lofgren S. M. Okafor E. C. (2020 ). A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl. J. Med. 383 (6), 517–525
Not in our library10.1056/nejmoa2016638
66.
Brennen S. Simon F. Howard P. N. Nielsen R. K. (2020 ). Types, sources, and claims of COVID-19 misinformation. Available at: https://reutersinstitute.politics.ox.ac.uk/types-sources-and-claims-covid-19-misinformation.
Not in our library
67.
Brooks S. K. Webster R. K. Smith L. E. Woodland L. Wessely S. Greenberg N. (2020 ). The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 395 (10227), 912–920.
Not in our library10.1016/s0140-6736(20)30460-8
68.
Bruton B. Edwards N. (2020 ). Barriers to mass testing for COVID-19 in Africa. Available at: https://www.atlanticcouncil.org/blogs/africasource/barriers-to-mass-testing-for-covid-19-in-africa/.
Not in our library
69.
Budoo A. (2020 ). In Africa, government attempts to fight misinformation are also limiting freedom of expression. Available at: https://www.niemanlab.org/2020/05/in-africa-government-attempts-to-fight-misinformation-are-also-limiting-freedom-of-expression/.
Not in our library
70.
Burke J. (2020 ). It's just beginning here': Africa turns to testing as pandemic grips the continent. Available at: https://www.msn.com/en-gb/news/world/its-just-beginning-here-africa-turns-to-testing-as-pandemic-grips-the-continent/ar-BB13de1l?ocid=spartandhp.
Not in our library
71.
Cadogan C. A. Hughes C. M. (2020 ). On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis. Res. Soc. Adm. Pharm.
Not in our library10.1016/j.sapharm.2020.03.015
72.
Campbell A. M. (2020 ). An increasing risk of family violence during the Covid-19 pandemic: Strengthening community collaborations to save lives. Forensic Sci. Int.: Rep. 2 100089.
Not in our library10.1016/j.fsir.2020.100089
73.
Cao B. Wang Y. Wen D. Liu W. Wang J. Fan G. (2020 ). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl. J. Med. 382 (19), 1787–1799.
Not in our library10.1056/nejmoa2001282
74.
Cash R. Patel V. (2020 ). The art of medicine - Has COVID-19 subverted global health? Lancet 395, 1687–1688.
Not in our library10.1016/s0140-6736(20)31089-8
75.
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis · 2019
No notice
76.
Castagnoli R. Votto M. Licari A. Brambilla I. Bruno R. Perlini S. (2020 ). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr.
Not in our library10.1001/jamapediatrics.2020.1467
77.
Centre for Disease Prevention and Control (2020 ). People Who Are at Higher Risk for Severe Illness. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fspecific-groups%2Fpeople-at-higher-risk.html.
Not in our library
78.
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 · 2020
No notice
79.
CGTN Africa (2020 ). Uganda urges public on HIV/AIDS spread amid COVID-19 pandemic. Available at: https://africa.cgtn.com/2020/05/06/uganda-urges-public-on-hiv-aids-spread-amid-covid-19-pandemic/.
Not in our library
80.
Chaiyachati K. H. Ogbuoji O. Price M. Suthar A. B. Negussie E. K. Bärnighausen T. (2014 ). Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS 28 (Suppl 2), S187–S204.
Not in our library10.1097/qad.0000000000000252
81.
Chan D. K. C. Zhang C. Q. Josefsson K. W. (2020 ). Why People Failed to Adhere to COVID-19 Preventive Behaviors? Perspectives from an Integrated Behavior Change Model. Infection Control Hosp. Epidemiol., 1–6.
Not in our library10.1017/ice.2020.245
82.
Chandan J. S. Taylor J. Bradbury-Jones C. Nirantharakumar K. Kane E. Bandyopadhyay S. (2020 ). COVID-19: a public health approach to manage domestic violence is needed. Lancet Public Health. 5 (6), e309
Not in our library10.1016/s2468-2667(20)30112-2
83.
Chang A. Y. Gómez-Olivé F. X. Manne-Goehler J. Wade A. N. Tollman S. Gaziano T. A. (2019 ). Multimorbidity and care for hypertension, diabetes and HIV among older adults in rural South Africa. Bull. World Health Organ 97 (1), 10–23.
Not in our library10.2471/blt.18.217000
84.
Channnel News Asia (2020 ). Malaysia still using hydroxychloroquine to treat COVID-19 patients; health ministry monitoring side effects. 26 May 2020. Available at: https://www.channelnewsasia.com/news/asia/covid-19-malaysia-hydroxychloroquine-still-using-treatment-12771770.
Not in our library
85.
Chauhan R. P. Dessie Z. G. Noreddin A. El Zowalaty M. E. (2020 ). Systematic Review of Important Viral Diseases in Africa in Light of the 'One Health' Concept. Pathog. 9 (4), 1–83.
Not in our library10.3390/pathogens9040301
86.
Chiang C. Y. El Sony A. (2020 ). Tackling the threat of COVID-19 in Africa: an urgent need for practical planning. Int. J. Tuberculosis Lung Dis. 24 (5), 541–542.
Not in our library10.5588/ijtld.20.0192
87.
Chigome A. K. Matlala M. Godman B. Meyer J. C. (2019 ). Availability and Use of Therapeutic Interchange Policies in Managing Antimicrobial Shortages among South African Public Sector Hospitals; Findings and Implications. Antibiotics 9 (1), 1–11.
Not in our library10.3390/antibiotics9010004
88.
Chilinda W. (2020 ). Government To Recruit 8,000 Health Work In 2020. Available at: https://www.znbc.co.zm/news/government-to-recruit-8000-health-work-in-2020/.
Not in our library
89.
Chowdhury M. S. Rathod J. Gernsheimer J. (2020 ). A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. Acad. Emergency Med. 27 (6), 493–504.
Not in our library10.1111/acem.14005
90.
Clinical Trials Arena (2020 ). Genentech's arthritis drug tocilizumab shows promise in Covid-19 trial. Available at: https://www.clinicaltrialsarena.com/news/french-early-trial-tocilizumab-covid-19/.
Not in our library
91.
Cohen I. G. Gostin L. O. Weitzner D. J. (2020 ). Digital Smartphone Tracking for COVID-19: Public Health and Civil Liberties in Tension. JAMA.
Not in our library10.1001/jama.2020.8570
92.
Conway M. Holt T. Sabow A. Sun I. Y. (2020 ). Should sub-Saharan Africa make its own drugs? Available at: https://www.mckinsey.com/industries/public-sector/our-insights/should-sub-saharan-africa-make-its-own-drugs
Not in our library
93.
Cortegiani A. Ingoglia G. Ippolito M. Giarratano A. Einav S. (2020 ). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care 57, 279–283.
Not in our library10.1016/j.jcrc.2020.03.005
94.
Coulibaly N. (2020 ). To fight coronavirus, Burkina Faso is tempted by chloroquine. Available at: https://www.theafricareport.com/25416/to-fight-coronavirus-burkina-faso-is-tempted-by-chloroquine/
Not in our library
95.
Council for International Organizations of Medical Sciences (2020 ). Medicines assessment during public health emergencies needs good science, best practices and proper communication. Available at: https://cioms.ch/wp-content/uploads/2020/06/CIOMS_WGXII_Statement.pdf.
Not in our library
96.
Courtemanche C. Garuccio J. Le A. Pinkston J. Yelowitz A. (2020 ). Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. Health Affairs.
Not in our library10.1377/hlthaff.2020.00608
97.
Craven M. Mysore M. Singhal S. Wilson M. (2020 ). COVID-19: Briefing note, April 13, 2020 - Our latest perspectives on the coronavirus pandemic. Available at: https://www.mckinsey.com/business-functions/risk/our-insights/covid-19-implications-for-business
Not in our library
98.
Cullen W. Gulati G. Kelly B. D. (2020 ). Mental health in the COVID-19 pandemic. QJM Monthly J. Assoc. Phys. 113 (5), 311–312.
Not in our library10.1093/qjmed/hcaa110
99.
Treatment of COVID-19: old tricks for new challenges · 2020
No notice
100.
da Silva W. C. de Araujo V. E. Lima E. Dos Santos J. B. R. Silva M. Almeida P. (2018 ). Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs 32 (6), 585–606.
Not in our library10.1007/s40259-018-0322-1
101.
Dabanga (2020 ). OCHA Sudan: Medical supplies may be affected by Covid-19 measures. Available at: https://www.dabangasudan.org/en/relief-news/article/ocha-sudan-medical-supplies-may-be-affected-by-covid-19-measures.
Not in our library
102.
Daily Monitor (2020 ). Uganda scientists develop devices to fight Covid-19. Available at: https://www.monitor.co.ug/News/National/Uganda-scientists-develop-devices-to-fight-Covid19/688334-5530170-11h0vedz/index.html.
Not in our library
103.
Das S. Bhowmick S. Tiwari S. Sen S. (2020 ). An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Clin. Drug Invest. 40 (7), 591–601.
Not in our library10.1007/s40261-020-00927-1
104.
Davis R. (2020 ). Viral outbreak: Fake news spreads in SA in tandem with Covid-19. Available at: https://www.dailymaverick.co.za/article/2020-03-31-viral-outbreak-fake-news-spreads-in-sa-in-tandem-with-covid-19/.
Not in our library
105.
Defy (2020 ). Doing Our Part. Available at: https://www.defy.co.za/doing-our-part/.
Not in our library
106.
Di Caro B. (2020 ). COVID-19 in Africa: insights from our 30 April WHO media briefing. Available at: https://www.weforum.org/agenda/2020/04/covid-19-in-africa-insights-from-our-30-april-who-media-briefing/.
Not in our library
107.
Di Lorenzo G. Di Trolio R. (2020 ). Coronavirus Disease (COVID-19) in Italy: Analysis of Risk Factors and Proposed Remedial Measures. Front. Med. 7 (140), 1–4.
Not in our library10.3389/fmed.2020.00140
108.
Dietz W. Santos-Burgoa C. (2020 ). Obesity and its Implications for COVID-19 Mortality. Obesity 28 (6), 1005.
Not in our library10.1002/oby.22818
109.
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study · 2020
No notice
110.
Donabedian A. (2005 ). Evaluating the quality of medical care. 1966. Milbank Q. 83 (4), 691–729.
Not in our library10.1111/j.1468-0009.2005.00397.x
111.
Du R. H. Liang L. R. Yang C. Q. Wang W. Cao T. Z. Li M. (2020 ). Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur. Respir. J. 55 (5), 2000524
Not in our library10.1183/13993003.00524-2020
112.
Ducomble T. Gignoux E. (2020 ). Learning from a massive epidemic: measles in DRC. Lancet Infect. Dis. 20 (5), 542.
Not in our library10.1016/s1473-3099(20)30265-6
113.
Dugmore H. (2020 ). Covid-19 leaves SA at the mercy of overseas drug exporters. Available at: https://mg.co.za/article/2020-03-25-covid-19-leaves-sa-at-the-mercy-of-overseas-drug-exporters/.
Not in our library
114.
Dyer O. (2020 ). Covid-19: Africa records over 10 000 cases as lockdowns take hold. BMJ (Clin. Res. Ed.) 369, m1439.
Not in our library10.1136/bmj.m1439
115.
EAC Secretariat (2020 ). East African Community COVID-19 Response Plan. Available at: https://www.eac.int/coronavirus.
Not in our library
116.
EAC (2020 ). EAC Partner States directed to support local production of essential medical products and supplies to combat COVID-19 in the region. Available at: https://www.eac.int/press-releases/147-health/1724-eac-partner-state-directed-to-support-local-prodcution-of-essential-medical-products-and-suupliees-to-combat-covid-19-in-the-region.
Not in our library
117.
East African (2020 ). Uganda endorses anti-malaria drug under clinical trial to cure Covid-19. Available at: https://www.monitor.co.ug/News/National/Uganda-endorses-anti-malaria-drug-clinical-trial-cure-Covid-19/688334-5531292-rob53m/index.html.
Not in our library
118.
Ebrahim E. Lakay B. (2020 ). Mkhize: Health sector must manage chronic patients amid Covid-19 - or it may bring a new challenge. Available at: https://www.health24.com/Medical/Infectious-diseases/Coronavirus/mkhize-health-sector-must-manage-chronic-patients-amid-covid-19-or-it-may-bring-a-new-challenge-20200430.
Not in our library
119.
ECDC (2020 a). Vaccines and treatment of COVID-19. Available at: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/vaccines-and-treatment.
Not in our library
120.
ECDC (2020 b). Ebola outbreak in the Democratic Republic of the Congo. Available at: https://www.ecdc.europa.eu/en/ebola-virus-disease-outbreak-democratic-republic-congo-ongoing.
Not in our library
121.
Editor Food Business Africa (2020 ). Trade Kings Foundation launches hygiene drive against Covid-19 in Lusaka. Available at: https://www.foodbusinessafrica.com/2020/04/22/trade-kings-foundation-launches-hygiene-drive-against-covid-19-in-lusaka/.
Not in our library
122.
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety · 2014
No notice
123.
Ellinghaus D. Degenhardt F. Bujanda L. Buti M. Albillos A. Invernizzi P. (2020 ). Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl. J. Med.
Not in our library10.1056/nejmoa2020283
124.
El-Sabaa R. (2020 ). Egypt's health ministry launches coronavirus mobile application. Available at: http://english.ahram.org.eg/NewsContent/1/64/367263/Egypt/Politics-/Egypts-health-ministry-launches-coronavirus-mobile.aspx.
Not in our library
125.
El-Sadr W. M. Justman J. (2020 ). Africa in the Path of Covid-19. N Engl. J. Med. 383 (3), e11.
Not in our library10.1056/nejmp2008193
126.
EMA (2020 ). First COVID-19 treatment recommended for EU authorisation. 25 June 2020. Available at: https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation.
Not in our library
127.
Endomba F. T. Wouna D. L. A. Danwang C. (2020 ). Mental health during the coronavirus disease 2019 (Covid-19) pandemic: more is still to be done. PAMJ 35 (2), 7.
Not in our library10.11604/pamj.supp.2020.35.2.22605
128.
Payers’ views of the changes arising through the possible adoption of Adaptive Pathways · 2016
Not checked
129.
European Medicine Agency (2020 a). COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine. Available at: https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine.
Not in our library
130.
European Medicines Agency (2020 b). EU authorities agree new measures to support availability of medicines used in the COVID-19 pandemic. Available at: https://www.ema.europa.eu/en/news/eu-authorities-agree-new-measures-support-availability-medicines-used-covid-19-pandemic.
Not in our library
131.
European Observatory (2016 ). How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe? Available at: http://www.euro.who.int/:data/assets/pdf_file/0009/331992/PB21.pdf?ua=1.
Not in our library
132.
EY Tax News Update (2020 ). Zambia issues additional fiscal measures to mitigate the impact of COVID-19. Available at: https://taxnews.ey.com/news/2020-1113-zambia-issues-additional-fiscal-measures-to-mitigate-the-impact-of-covid-19?uAlertID=Sd%2FG8rua1oj6%2Fl58EZ2AiA%3D%3D.
Not in our library
133.
Fang L. Karakiulakis G. Roth M. (2020 ). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 8 (4), e21.
Not in our library10.1016/s2213-2600(20)30116-8
134.
Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status · 2020
Not checked
135.
Ferner R. E. Aronson J. K. (2020 ). Chloroquine and hydroxychloroquine in covid-19. BMJ 369, m1432.
Not in our library10.1136/bmj.m1432
136.
Ferrario A. Arāja D. Bochenek T. Čatić T. Dankó D. Dimitrova M. (2017 ). The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. PharmacoEconomics 35 (12), 1271–1285.
Not in our library10.1007/s40273-017-0559-4
137.
Ford N. Vitoria M. Rangaraj A. Norris S. L. Calmy A. Doherty M. (2020 ). Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J. Int. AIDS Soc. 23 (4), e25489.
Not in our library10.1002/jia2.25489
138.
Forrest A. (2020 ). Coronavirus: 700 dead in Iran after drinking toxic methanol alcohol to cure Covid-19. Available at: https://www.msn.com/en-gb/news/coronavirus/coronavirus-700-dead-in-iran-after-drinking-toxic-methanol-alcohol-to-cure-covid-19/ar-BB13jC6f?ocid=spartandhp.
Not in our library
139.
Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis · 2017
No notice
140.
Gaborit B. J. Bergmann J. F. Mussini C. Arribas J. R. Behrens G. Walmsley S. (2020 ). Plea for multitargeted interventions for severe COVID-19. Lancet Infect. Dis.
Not in our library10.1016/s1473-3099(20)30312-1
141.
Gallagher F. (2020 ). Tracking hydroxychloroquine misinformation: How an unproven COVID-19 treatment ended up being endorsed by Trump. ABC News. Available at: https://abcnews.go.com/Health/tracking-hydroxychloroquine-misinformation-unproven-covid-19-treatment-ended/story?id=70074235.
Not in our library
142.
Gao J. Tian Z. Yang X. (2020 ). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends 14 (1), 72–73.
Not in our library10.5582/bst.2020.01047
143.
Gautret P. Lagier J. C. Parola P. Hoang V. T. Meddeb L. Mailhe M. (2020 ). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 105949.
Not in our library10.1016/j.ijantimicag.2020.105949
144.
Use of Rapid Online Surveys to Assess People's Perceptions During Infectious Disease Outbreaks: A Cross-sectional Survey on COVID-19 · 2020
No notice
145.
Geleris J. Sun Y. Platt J. Zucker J. Baldwin M. Hripcsak G. (2020 ). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl. J. Med. 382 (25), 2411–2418.
Not in our library10.1056/nejmoa2012410
146.
Ghana Ministry of Health (2018 ). Ministry of Food and Agriculture, Ministry of Environment, Science, Technology and Innovation, Ministry of Fisheries and Aquaculture Development. Ghana National Action Plan for Antimicrobial Use and Resistance. 2017 - 2021. Available at: http://www.moh.gov.gh/wp-content/uploads/2018/04/NAP_FINAL_PDF_A4_19.03.2018-SIGNED-1.pdf.
Not in our library
147.
Ghana News Agency (2020 ). Successful testing regime and controls inform lifting of lockdown. Issued April 20 2020. Available at: https://newsghana.com.gh/successful-testing-regime-and-controls-inform-lifting-of-lockdown/.
Not in our library
148.
Ghana Prorities Project (2020 ). A rapid cost-benefit analysis of moderate social distancing in response to the COVID-19 pandemic in Ghana. 20 May 2020. Available at: https://www.copenhagenconsensus.com/sites/default/files/covid_brief_for_ndpc_ghana_final.pdf.
Not in our library
149.
GhanaWeb (2020 a). Pharmaceutical companies to produce 70% of country's drug needs. Available at: https://www.ghanaweb.com/GhanaHomePage/NewsArchive/Pharmaceutical-companies-to-produce-70-of-country-s-drug-needs-936016.
Not in our library
150.
GhanaWeb (2020 b). Coronavirus: Stop discriminating against recovered patients. Available at: https://www.ghanaweb.com/GhanaHomePage/NewsArchive/Coronavirus-Stop-discriminating-against-recovered-patients-Fred-Drah-926353.
Not in our library
151.
Ghosal A. Milko V. Coronavirus could erode global fight against other diseases. Available at: https://www.msn.com/en-gb/news/world/coronavirus-could-erode-global-fight-against-other-diseases/ar-BB12HxuG?ocid=spartandhp#image=1.
Not in our library
152.
Global Coronavirus COVID-19 Clinical Trial Tracker. (2020 ). Available at: https://www.covid-trials.org/.
Not in our library
153.
Glied S. Levy H. (2020 ). The Potential Effects of Coronavirus on National Health Expenditures. JAMA.
Not in our library10.1001/jama.2020.6644
154.
Godman B. Wettermark B. van Woerkom M. Fraeyman J. Alvarez-Madrazo S. Berg C. (2014 ). Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front. Pharmacol. 5, 106.
Not in our library10.3389/fphar.2014.00106
155.
Godman B. Malmstrom R. E. Diogene E. Jayathissa S. McTaggart S. Cars T. (2014 b). Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front. Pharmacol. 5, 109.
Not in our library10.3389/fphar.2014.00109
156.
Godman B. Malmstrom R. E. Diogene E. Gray A. Jayathissa S. Timoney A. (2015 ). Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev. Clin. Pharmacol. 8 (1), 77–94.
Not in our library10.1586/17512433.2015.990380
157.
Godman B. Bucsics A. Vella Bonanno P. Oortwijn W. Rothe C. C. Ferrario A. (2018 ). Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Front. Public Health 6, 328.
Not in our library10.3389/fpubh.2018.00328
158.
Godman B. Grobler C. Van-De-Lisle M. Wale J. Barbosa W. B. Massele A. (2019 ). Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opin. Pharmacother. 20 (18), 2237–2255.
Not in our library10.1080/14656566.2019.1684473
159.
Godman B. (2020 ). Combating COVID-19: Lessons learnt particularly among developing countries and the implications. Bangladesh J. Med. Sci. S103–8.
Not in our library10.3329/bjms.v19i0.48413
160.
Godman B. Haque M. McKimm J. Abu Bakar M. Sneddon J. Wale J. (2020 a). Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. Curr. Med. Res. Opin. 36 (2), 301–327.
Not in our library10.1080/03007995.2019.1700947
161.
Godman B. Basu D. Pillay Y. Almeida P. Mwita J. C. Rwegerera G. M. (2020 b). Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. Hosp. Pract. 48 (2), 51–67.
Not in our library10.1080/21548331.2020.1745509
162.
Godman B. Basu D. Pillay Y. Mwita J. C. Rwegerera G. M. Anand Paramadhas B. D. (2020 c). Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. Front. Pharmacol. 11 (108), 1–21.
Not in our library10.3389/fphar.2020.00108
163.
Godman B. McCabe H. Leong T. D. (2020 d). Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev. Pharmacoecon. Outc. Res. 20 (1), 1–26.
Not in our library10.1080/14737167.2020.1734456
164.
González-Sanguino C. Ausín B. Castellanos M. Saiz J. López-Gómez A. Ugidos C. (2020 ). Mental health consequences during the initial stage of the 2020 Coronavirus pandemic (COVID-19) in Spain. Brain Behav. Immun.
Not in our library10.1016/j.bbi.2020.05.040
165.
Goodman J. L. Borio L. (2020 ). Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis. JAMA 87, 172–176.
Not in our library10.1001/jama.2020.6434
166.
Gounden P. Barden C. Charter C. (2020 ). Taking stock: Competition law's response to the novel COVID-19 outbreak. Available at: https://www.cliffedekkerhofmeyr.com/en/news/publications/2020/Competition/competition-alert-1-april-Taking-stock-Competition-laws-response-to-the-novel-COVID-19-outbreak.html.
Not in our library
167.
Government of The Kingdom of Eswatini (2020 ). Prime Minister's Statement - Partial Lockdown Strengthened Measures. Available at: http://www.gov.sz/images/CORONA/PM-statement-22-April-2020.pdf.
Not in our library
168.
Gower P. (2020 ). UP produces interactive app with real-time data on COVID-19 infections. Available at: https://www.up.ac.za/news/post_2885914-up-produces-interactive-app-with-real-time-data-on-covid-19-infections.
Not in our library
169.
Guan W.-J. Ni Z.-Y. Hu Y. Liang W.-H. Ou C.-Q. He J.-X. (2020 ). Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl. J. Med. 382 (18), 1708–1720.
Not in our library10.1056/nejmoa2002032
170.
Guo W. Ming F. Dong Y. Zhang Q. Zhang X. Mo P. (2020 ). A Survey for COVID-19 Among HIV/AIDS Patients in Two Districts of Wuhan, China. Lancet.
Not in our library
171.
GuruGamer (2020 ). Warning: An American Died Of Using A Chloroquine Overdose Suggested As A Coronavirus Cure By President Trump. Available at: https://gurugamer.com/features/an-american-died-of-using-a-chloroquine-overdose-suggested-as-a-coronavirus-cure-by-president-trump-9466.
Not in our library
172.
Habersaat K. B. Betsch C. Danchin M. Sunstein C. R. Böhm R. Falk A. (2020 ). Ten considerations for effectively managing the COVID-19 transition. Nat. Hum. Behav. 4 (7), 677–687.
Not in our library10.1038/s41562-020-0906-x
173.
Haigh L. (2020 ). Malaria in Zimbabwe exacerbated by Covid-19. Available at: https://www.itij.com/latest/news/malaria-zimbabwe-exacerbated-covid-19.
Not in our library
174.
Hall C. (2020 ). This One Thing Could Be the Key to Reducing the Progression of COVID-19. Available at: https://www.msn.com/en-us/health/medical/this-one-thing-could-be-the-key-to-reducing-the-progression-of-covid-19/ar-BB12Wb84.
Not in our library
175.
Hamid S. Mir M. Y. Rohela G. K. (2020 ). Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 35, 100679.
Not in our library10.1016/j.nmni.2020.100679
176.
Haque M. Islam S. Iqbal S. Urmi U. L. Kamal Z. M. Shuvo S. A. (2020 ). Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bangladesh J. Med. Sci. 19 (Special Issue on Covid19), S36–S50.
Not in our library
177.
Härter G. Spinner C. D. Roider J. Bickel M. Krznaric I. Grunwald S. (2020 ). COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection, 1–6.
Not in our library10.1007/s15010-020-01438-z
178.
Hatswell A. J. (2020 ). Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic. PharmacoEconom. - Open 4 (2), 203–205.
Not in our library10.1007/s41669-020-00216-9
179.
Hayat K. Rosenthal M. Xu S. Arshed M. Li P. Zhai P. (2020 ). View of Pakistani Residents toward Coronavirus Disease (COVID-19) during a Rapid Outbreak: A Rapid Online Survey. Int. J. Environ. Res. Public Health 17 (10), 1–10.
Not in our library10.3390/ijerph17103347
180.
He J. He L. Zhou W. Nie X. He M. (2020 ). Discrimination and Social Exclusion in the Outbreak of COVID-19. Int. J. Environ. Res. Public Health 17 (8), 1–4.
Not in our library10.3390/ijerph17082933
181.
Health 24 (2020 ). Dramatic drop in SA's immunisation rates. 26 June 2020. Available at: https://www.health24.com/Medical/Childhood-diseases/Vaccinations/dramatic-drop-in-sas-immunisation-rates-20200624-4.
Not in our library
182.
Hedima E. W. Adeyemi M. S. Ikunaiye N. Y. (2020 ). Community Pharmacists: On the frontline of health service against COVID-19 in LMICs. Res. Soc. Adm. Pharm.
Not in our library10.1016/j.sapharm.2020.04.017
183.
Hernandez-Villafuerte K. Li R. Hofman K. J. (2016 ). Bibliometric trends of health economic evaluation in Sub-Saharan Africa. Global Health 12 (1), 50.
Not in our library10.1186/s12992-016-0188-2
184.
High Commission of the Republic of Zambia (2020 ). Statement by the Hon. Minister of finance on covid-19. Available at: https://www.zambiahc.org.uk/news_events/statement-by-the-hon-minister-of-finance-on-covid-19/.
Not in our library
185.
Ho U. (2020 ). Covid-19 precaution: Some patients on chronic meds to have prescriptions filled for up to four months. Sportlight Health Journalism. 31 March 2020. Available from URL: http://www.msn.com/en-za/health/healthnews/covid-19-precaution-some-patients-on-chronic-meds-to-have-prescriptions-filled-for-up-to-four-months/ar-BB11VVGr
Not in our library
186.
Hofer U. (2019 ). The cost of antimicrobial resistance. Nat. Rev. Microbiol. 17 (1), 3.
Not in our library10.1038/s41579-018-0125-x
187.
Hofman K. Goldstein S. (2020 ). COVID-19 risks forcing SA to make health trade-offs it can ill afford. Available at: https://www.wits.ac.za/covid19/covid19-news/latest/covid-19-risks-forcing-sa-to-make-health-trade-offs-it-can-ill-afford.html.
Not in our library
188.
Hollingworth S. Odame E. Winch A. (2018 ). Understanding data needs for HTA in Sub-Saharan Africa – a framework and Ghana case study. Available at: https://www.idsihealth.org/wp-content/uploads/2018/10/Data-Sources-.pdf.
Not in our library
189.
Houreld K. Lewis D. (2020 ). In Africa, lack of coronavirus data raises fears of silent epidemic. 8 July 2020. Available at: https://www.yahoo.com/news/africa-lack-coronavirus-data-raises-081603106.html
Not in our library
190.
Houreld K. Lewis D. McNeill R. Granado S. (2020 ). Virus exposes gaping holes in Africa's health systems. Available at: https://graphics.reuters.com/HEALTH-CORONAVIRUS/AFRICA/yzdpxoqbdvx/?fbclid=IwAR2Xu9J5CLPuUfxWyzFzi-uiSlixjgxsJDPXh0Loa40HNnEnisi0glXCG_A.
Not in our library
191.
Huang C. Wang Y. Li X. Ren L. Zhao J. Hu Y. (2020 ). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (10223), 497–506.
Not in our library10.1016/s0140-6736(20)30183-5
192.
Huang I. Lim M. A. Pranata R. (2020 ). Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metab. Syndrome 14 (4), 395–403.
Not in our library10.1016/j.dsx.2020.04.018
193.
Hung I. F.-N. Lung K.-C. Tso E. Y.-K. Liu R. Chung T. W.-H. Chu M.-Y. (2020 ). Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395 (10238), 1695–1704.
Not in our library10.1016/s0140-6736(20)31042-4
194.
Loneliness and social isolation during the COVID-19 pandemic · 2020
No notice
195.
IFRC, UNICEF and WHO (2020 ). Social Stigma associated with COVID-19. Available at: https://reliefweb.int/sites/reliefweb.int/files/resources/covid19-stigma-guide.pdf.
Not in our library
196.
Ighobor K. (2020 ). Together we can win the war against COVID-19. Available at: https://www.un.org/africarenewal/magazine/special-edition-covid-19/together-we-can-win-war-against-covid-19.
Not in our library
197.
IHME (2020 a). New COVID-19 forecasts for Europe: Italy & Spain have passed the peak of their epidemics; UK, early in its epidemic, faces a fast-mounting death toll. Available at: http://www.healthdata.org/news-release/new-covid-19-forecasts-europe-italy-spain-have-passed-peak-their-epidemics-uk-early-its.
Not in our library
198.
IHME (2020 b). New COVID-19 forecasts: US hospitals could be overwhelmed in the second week of April by demand for ICU beds, and US deaths could total 81,000 by July. Available at: http://www.healthdata.org/news-release/new-covid-19-forecasts-us-hospitals-could-be-overwhelmed-second-week-april-demand-icu.
Not in our library
199.
IMF (2020 ). IMF Executive Board Approves a US$491.5 Million Disbursement to Uganda to Address the COVID-19 Pandemic. Available at: https://www.imf.org/en/News/Articles/2020/05/06/pr20206-uganda-imf-executive-board-approves-us-million-disbursement-address-the-covid-19-pandemic.
Not in our library
200.
Inciardi R. M. Lupi L. Zaccone G. Italia L. Raffo M. Tomasoni D. (2020 ). Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 5 (7), 1–6.
Not in our library10.1001/jamacardio.2020.1096
201.
International Alliance of Patients' Organizations (2020 ). COVID-19 Resources Hub. Available at: https://www.iapo.org.uk/covid-19-resources-hub.
Not in our library
202.
International Society of Antimicrobial Chemotherapy (2020 ). Official Statement from International Society of Antimicrobial Chemotherapy (ISAC) - Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (Gautret P et al. PMID 32205204). Available at: https://www.isac.world/news-and-publications/official-isac-statement.
Not in our library10.1016/j.ijantimicag.2020.105949
203.
IOL (2020 ). In a Covid-19 world, telemedicine will be the new normal. Available at: https://www.iol.co.za/lifestyle/health/in-a-covid-19-world-telemedicine-will-be-the-new-normal-47357559.
Not in our library
204.
ISAC/ Elsevier (2020 ). Joint ISAC and Elsevier statement on Gautret et al. paper [PMID 32205204]. Available at: https://www.isac.world/news-and-publications/isac-elsevier-statement.
Not in our library
205.
Jayaram K. Leke A. Ooko-Ombaka A. Sun Y. S. (2020 ). Tackling COVID-19 in Africa - An unfolding health and economic crisis that demands bold action. Available at: https://www.mckinsey.com/featured-insights/middle-east-and-africa/tackling-covid-19-in-africa#.
Not in our library
206.
Jerving S. (2020 ). How COVID-19 could complicate treatment for HIV patients. Available at: https://www.devex.com/news/how-covid-19-could-complicate-treatment-for-hiv-patients-96884.
Not in our library
207.
JKUAT (2020 a). JKUAT Trio Develop Apps to Trace, Triage and Manage COVID-19. Available at: http://www.jkuat.ac.ke/jkuat-trio-develop-contact-tracing-and-case-management-apps/.
Not in our library
208.
JKAUT (2020 b). JKUAT's Team of Engineers Invent Ventilators to Fill Shortage. Available at: http://www.jkuat.ac.ke/jkuats-team-of-engineers-invent-ventilators-to-fill-shortage/.
Not in our library
209.
Jones A. (2020 ). Coronavirus: How 'overreaction' made Vietnam a virus success. Available at: https://www.bbc.co.uk/news/world-asia-52628283.
Not in our library
210.
Jose R. J. Manuel A. (2020 ). COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir. Med. 8 (6), e46–e47.
Not in our library10.1016/s2213-2600(20)30216-2
211.
Journal du Cameroun (2020 ). Cameroon: Monkey pox hits East region, kills one. Available at: https://www.journalducameroun.com/en/cameroon-monkey-pox-hits-east-region-kills-one/.
Not in our library
212.
Kabale N. Otsialo M. Makong B. Njeru A. Muchui D. Chepngeno E. (2020 ). Concern as patients shun health centres. Available at: https://www.nation.co.ke/news/Concern-as-patients-shun-health-centres/1056-5543778-13ejdvwz/index.html.
Not in our library
213.
Kaine E. Nwokik J. (2020 ). Scaling Up African Pharmaceutical Manufacturing in a Time of COVID-19. Available at: https://www.cfr.org/blog/scaling-african-pharmaceutical-manufacturing-time-covid-19.
Not in our library
214.
Kalungia A. Godman B. (2019 ). Implications of non-prescription antibiotic sales in China. Lancet Infect. Dis. 19 (12), 1272–1273.
Not in our library10.1016/s1473-3099(19)30408-6
215.
Kalungia A. C. Burger J. Godman B. Costa J. O. Simuwelu C. (2016 ). Non-prescription sale and dispensing of antibiotics in community pharmacies in Zambia. Expert Rev. Anti-Infe. Ther. 14 (12), 1215–1223.
Not in our library10.1080/14787210.2016.1227702
216.
Kansiime S. Mwesigire D. Mugerwa H. (2019 ). Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda. PLoS One 14 (8), e0221022.
Not in our library10.1371/journal.pone.0221022
217.
Kasozi K. I. Mujinya R. Bogere P. Ekou J. Zirintunda G. Ahimbisibwe S. (2020 ). Pandemic panic and anxiety in developing countries. Embracing One Health offers practical strategies in management of COVID-19 for Africa. PAMJ 35 (2):3.
Not in our library10.11604/pamj.supp.2020.35.2.22637
218.
Kaufman K. R. Petkova E. Bhui K. S. Schulze T. G. (2020 ). A global needs assessment in times of a global crisis: world psychiatry response to the COVID-19 pandemic. BJPsych. Open 6 (3), e48.
Not in our library10.1192/bjo.2020.25
219.
Kavanagh M. M. Erondu N. A. Tomori O. Dzau V. J. Okiro E. A. Maleche A. (2020 ). Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet 395 (10238), 1735–1738.
Not in our library10.1016/s0140-6736(20)31093-x
220.
KCE Report (2017 ). KCE Report number 283. Horizon Scanning For Pharmaceuticals: Proposal For The Beneluxa Collaboration. Available at: http://www.beneluxa.org/sites/beneluxa.org/files/2017-07/Horizon%20scanning_ScientificReport_full.pdf.
Not in our library
221.
Keates A. K. Mocumbi A. O. Ntsekhe M. Sliwa K. Stewart S. (2017 ). Cardiovascular disease in Africa: epidemiological profile and challenges. Nat. Rev. Cardiol. 14 (5), 273–293.
Not in our library10.1038/nrcardio.2017.19
222.
Kenna H. A. Poon A. W. de los Angeles C. P. Koran L. M. (2011 ). Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin. Neurosci. 65 (6), 549–560.
Not in our library10.1111/j.1440-1819.2011.02260.x
223.
Kenyatta University (2020 ). K.U Makes Ventilators. Available at: http://www.ku.ac.ke/component/k2/item/1655-k-u-makes-ventilators.
Not in our library
224.
Khan M. S. Durrance-Bagale A. Legido-Quigley H. Mateus A. Hasan R. Spencer J. (2019 ). ‘LMICs as reservoirs of AMR': a comparative analysis of policy discourse on antimicrobial resistance with reference to Pakistan. Health Policy Plan 34 (3), 178–187.
Not in our library10.1093/heapol/czz022
225.
Khan M. S. Bory S. Rego S. Suy S. Durrance-Bagale A. Sultana Z. (2020 ). Is enhancing the professionalism of healthcare providers critical to tackling antimicrobial resistance in low- and middle-income countries? Hum. Resour. Health 18 (1), 10.
Not in our library10.1186/s12960-020-0452-7
226.
Khunti K. Singh A. K. Pareek M. Hanif W. (2020 ). Is ethnicity linked to incidence or outcomes of covid-19? BMJ 369, m1548.
Not in our library10.1136/bmj.m1548
227.
Kindzeka M. E. (2019 a). More Deaths Feared From Cholera in Cameroon. Available at: https://www.voanews.com/africa/more-deaths-feared-cholera-cameroon.
Not in our library
228.
Kindzeka M. E. (2019 b). Cameroon Launches Vaccination Campaign to Contain Measles Outbreak. Available at: https://www.voanews.com/africa/cameroon-launches-vaccination-campaign-contain-measles-outbreak.
Not in our library
229.
Kindzeka M. K. (2020 ). Cameroon Seizes Fake Coronavirus Drugs Sold by Scammers. Available at: https://www.voanews.com/science-health/coronavirus-outbreak/cameroon-seizes-fake-coronavirus-drugs-sold-scammers.
Not in our library
230.
Kirby T. (2020 ). Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Respir. Med. 8 (6), 547–548.
Not in our library10.1016/s2213-2600(20)30228-9
231.
Kluge H. H. P. Wickramasinghe K. Rippin H. L. Mendes R. Peters D. H. Kontsevaya A. (2020 ). Prevention and control of non-communicable diseases in the COVID-19 response. Lancet 395 (10238), 1678–1680.
Not in our library10.1016/s0140-6736(20)31067-9
232.
Knott S. (2020 ). Covid-19 could mark a deadly turn in Ghana's fight against fake drugs. Available at: https://www.theguardian.com/global-development/2020/apr/30/covid-19-could-mark-a-deadly-turn-in-ghana-fight-against-fake-drugs.
Not in our library
233.
Kowalska J. D. Skrzat-Klapaczyńska A. Bursa D. Balayan T. Begovac J. Chkhartishvili N. (2020 ). HIV care in times of the COVID-19 crisis - where are we now in Central and Eastern Europe? Int. J. Infect. Dis. 96, 311–314.
Not in our library10.1016/j.ijid.2020.05.013
234.
Kozloff N. Mulsant B. H. Stergiopoulos V. Voineskos A. N. (2020 ). The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. Schizophr. Bull. 46 (4), 752–757.
Not in our library10.1093/schbul/sbaa051
235.
Kretchy I. A. Asiedu-Danso M. Kretchy J. P. (2020 ). Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. Res. Soc. Adm. Pharm.
Not in our library10.1016/j.sapharm.2020.04.007
236.
Krubiner C. Keller J. M. Kaufman J. (2020 ). Balancing the COVID-19 Response with Wider Health Needs: Key Decision-Making Considerations for Low- and Middle-Income Countries. Available at: https://www.cgdev.org/sites/default/files/balancing-covid-19-response-wider-health-needs-key-decision-making-considerations-low.pdf.
Not in our library
237.
Kumar S. U. Kumar D. T. Christopher B. P. Doss C. G. P. (2020 ). The Rise and Impact of COVID-19 in India. Front. Med. 7, 250.
Not in our library10.3389/fmed.2020.00250
238.
Kumwenda T. (2020 ). CFTC Cautions 11 Pharmacies On Over-charging Items. Available at: https://www.zodiakmalawi.com/nw/national-news/64-news-in-northern-region/1528-cftc-cautions-11-pharmacies-on-over-charging-items.
Not in our library
239.
Kyeyune H. (2020 ). Shutdown in Uganda over COVID-19 hits poor hard - Times tough not only due to fears of infection but also because of poverty, says shop owner. Available at: https://www.aa.com.tr/en/africa/shutdown-in-uganda-over-covid-19-hits-poor-hard/1787526.
Not in our library
240.
Lacobucci G. (2020 ). NICE issues covid-19 critical care guideline. BMJ 368, m1177.32217519
Not in our library
241.
Lakay B. (2020 ). Your 6-month prescription expiring? Your pharmacist may extend it, new regulations state. Available at: https://www.health24.com/Medical/Infectious-diseases/Coronavirus/your-6-month-prescription-expiring-your-pharmacist-may-extend-it-new-regulations-state-20200430-2.
Not in our library
242.
LaMarca S. (2020 ). Scientists In Senegal Developed A $1 COVID-19 Testing Kit And Plan To Export Millions To African Countries. Available at: https://tanksgoodnews.com/2020/04/29/senegal-1-testing-kit/.
Not in our library
243.
Lancet editorial (2020 ). COVID-19 in Africa: no room for complacency. Lancet 395, 1669.
Not in our library10.1016/s0140-6736(20)31237-x
244.
Lapolla P. Mingoli A. Lee R. (2020 ). Deaths from COVID-19 in healthcare workers in Italy - what can we learn? Infection Control Hosp. Epidemiol. 1–4.
Not in our library10.1017/ice.2020.241
245.
Larson H. (2020 ). Blocking information on COVID-19 can fuel the spread of misinformation - Governments need to think twice before they suppress messages related to COVID-19. Nature 580, 306.
Not in our library10.1038/d41586-020-00920-w
246.
Le Roux C. Dramowski A. (2020 ). Personal protective equipment (PPE) in a pandemic: Approaches to PPE preservation for South African healthcare facilities. S. Afr. Med. J. 110 (6), 466–468.
Not in our library10.7196/samj.2020.v110i6.14831
247.
Li Q. Guan X. Wu P. Wang X. Zhou L. Tong Y. (2020 ). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl. J. Med. 382 (13), 1199–1207.
Not in our library10.1056/nejmoa2001316
248.
Progression of Mental Health Services during the COVID-19 Outbreak in China · 2020
No notice
249.
LinksCommunity (2020 ). Leveraging Technology to Improve Health Care During the COVID-19 Pandemic and Beyond. Available at: https://linkscommunity.org/assets/PDFs/cov039_telemedicine_v3_14may2020.pdf.
Not in our library
250.
Littlejohn E. (2020 ). Hydroxychloroquine use in the COVID-19 patient. Cleveland Clin. J. Med.
Not in our library10.3949/ccjm.87a.ccc011
251.
Liwa A. C. Smart L. R. Frumkin A. Epstein H.-A. B. Fitzgerald D. W. Peck R. N. (2014 ). Traditional herbal medicine use among hypertensive patients in sub-Saharan Africa: a systematic review. Curr. Hypertens. Rep. 16 (6), 437.
Not in our library10.1007/s11906-014-0437-9
252.
Logie C. H. (2020 ). Lessons learned from HIV can inform our approach to COVID-19 stigma. J. Int. AIDS Soc. 23, e25504.
Not in our library10.1002/jia2.25504
253.
Lorgelly P. K. Adler A. (2020 ). Impact of a Global Pandemic on Health Technology Assessment. Appl. Health Econ. Health Policy 18 (3), 339–343
Not in our library10.1007/s40258-020-00590-9
254.
Lubega M. Ekol J. E. (2020 ). Preparing communities to receive persons recently suspected or diagnosed with COVID-19. Pan Afr. Med. J. 35 (2), 21.
Not in our library10.11604/pamj.supp.2020.35.2.23202
255.
Luo L. Jiang J. Wang C. Fitzgerald M. Hu W. Zhou Y. (2020 ). Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharm. Sin. B.
Not in our library10.1016/j.apsb.2020.05.007
256.
Luo P. Liu Y. Qiu L. Liu X. Liu D. Li J. (2020 ). Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol. 92 (7), 814–818.
Not in our library10.1002/jmv.25801
257.
Luo E. Zhang D. Luo H. Liu B. Zhao K. Zhao Y. (2020 ). Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin. Med. 15 (34), 1–13.
Not in our library10.1186/s13020-020-00317-x
258.
Lusakatimes (2020 ). Government Suspended customs duties and VAT on additional medical supplies used in the fight against COVID-19. Available at: https://www.lusakatimes.com/2020/04/20/government-suspended-customs-duties-and-vat-on-additional-medical-supplies-used-in-the-fight-against-covid-19/.
Not in our library
259.
Mabuka-Maroa J. (2020 ). Few clinical trials are done in Africa: COVID-19 shows why this urgently needs to change. Available at: https://theconversation.com/few-clinical-trials-are-done-in-africa-covid-19-shows-why-this-urgently-needs-to-change-135117.
Not in our library
260.
MacQuilkan K. Baker P. Downey L. Ruiz F. Chalkidou K. Prinja S. (2018 ). Strengthening health technology assessment systems in the global south: a comparative analysis of the HTA journeys of China, India and South Africa. Glob. Health Action 11 (1), 1527556.
Not in our library10.1080/16549716.2018.1527556
261.
Mahase E. (2020 a). Doctors welcome critical care audit of covid-19 patient. BMJ 368, m1201.
Not in our library10.1136/bmj.m1201
262.
Mahase E. (2020 b). Covid-19: EU states report 60% rise in emergency calls about domestic violence. BMJ 369, m1872.
Not in our library10.1136/bmj.m1872
263.
Manfredi G. Kotzalidis G. D. Sani G. Koukopoulos A. E. Savoja V. Lazanio S. (2010 ). Persistent interferon-ß-1b-induced psychosis in a patient with multiple sclerosis. Psychiatry Clin. Neurosci. 64 (5), 584–586.
Not in our library10.1111/j.1440-1819.2010.02122.x
264.
Marini J. J. Gattinoni L. (2020 ). Management of COVID-19 Respiratory Distress. JAMA.
Not in our library10.1001/jama.2020.6825
265.
Markovic-Pekovic V. Grubisa N. Burger J. Bojanic L. Godman B. (2017 ). Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications. J. Res. Pharm. Pract. 6 (2), 120–125.
Not in our library10.4103/jrpp.jrpp_17_12
266.
Marra L. P. Araujo V. E. Silva T. B. Diniz L. M. Guerra Junior A. A. Acurcio F. A. (2016 ). Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Ther. 7 (2), 241–258.
Not in our library10.1007/s13300-016-0166-y
267.
Martinez-Alvarez M. Jarde A. Usuf E. Brotherton H. Bittaye M. Samateh A. L. (2020 ). COVID-19 pandemic in west Africa. Lancet Global Health 8 (5), e631–e632.
Not in our library10.1016/s2214-109x(20)30123-6
268.
Masango T. A. (2020 ). Misuse of chloroquine, azithromycin and lopinavir-ritonavir for the prevention and/or potential treatment of Covid-19. Available at: https://www.biznews.com/briefs/2020/03/24/pharmacy-body-anti-malaria-drugs-covid-19.
Not in our library
269.
Masina L. (2020 a). Malawi President Announces New Measures Against Coronavirus. Available at: https://www.voanews.com/covid-19-pandemic/malawi-president-announces-new-measures-against-coronavirus.
Not in our library
270.
Masina L. (2020 b). UN in Malawi Launches Emergency Appeal for COVID-19 Response. Available at: https://www.voanews.com/covid-19-pandemic/un-malawi-launches-emergency-appeal-covid-19-response.
Not in our library
271.
Massonnaud C. Roux J. Crépey P. (2020 ). COVID-19: Forecasting short term hospital needs in France. MedRxiv preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.03.16.20036939v1.full.pdf.
Not in our library10.1101/2020.03.16.20036939
272.
Matengo D. (2019 ). Cameroon declares polio emergency. Available at: https://africa.cgtn.com/2019/06/01/cameroon-declares-polio-emergency/.
Not in our library
273.
Matos R. I. Chung K. K. (2020 ). DoD COVID-19 Practice Management Guide. Available at: http://www.med.umich.edu/surgery/mcccn/documents/DoD-COVID-19-Practice-Management-Guide-V10.
Not in our library
274.
Matshediso M. (2020 ). Gauteng Health adds COVID-19 feature to Mpilo App. Available at: https://www.vukuzenzele.gov.za/gauteng-health-adds-covid-19-feature-mpilo-app.
Not in our library
275.
Mbuagbaw L. Sivaramalingam B. Navarro T. Hobson N. Keepanasseril A. Wilczynski N. J. (2015 ). Interventions for Enhancing Adherence to Antiretroviral Therapy (ART): A Systematic Review of High Quality Studies. AIDS patient Care STDs 29 (5), 248–266.
Not in our library10.1089/apc.2014.0308
276.
McCaffrey D. (2020 ). Analysis: Africa's unexpected COVID-19 figures. Available at: https://www.euronews.com/2020/05/12/analysis-africa-s-unexpected-covid-19-figures.
Not in our library
277.
McMaster University. COVID-END (2020 ). COVID-19 Evidence Network to support Decision-making. Available at: https://www.mcmasterforum.org/networks/covid-end.
Not in our library
278.
Media Foundation West Africa (2020 ). Curbing Misinformation in a COVID -19 Era, Ghana's Approach. Available at: https://www.mfwa.org/issues-in-focus/curbing-misinformation-in-a-covid-19-era-ghanas-approach/.
Not in our library
279.
Medical Brief (2020 a). Cape Town's BCG trials threatened by demands from advocacy group. Available at: https://www.medicalbrief.co.za/archives/cape-towns-bcg-trials-threatened-by-demands-from-advocacy-group/.
Not in our library
280.
Medical Brief (2020 b). Health Department 'taking steps' over shortage of antidepressants and antipsychotics. Available at: https://www.medicalbrief.co.za/archives/health-department-taking-steps-over-shortage-of-antidepressants-and-antipsychotics/.
Not in our library
281.
Mehra M. R. Desai S. S. Ruschitzka F. Patel A. N. (2020 ). Retracted: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet.
Not in our library10.1016/s0140-6736(20)31180-6
282.
Mehta H. B. Ehrhardt S. Moore T. J. Segal J. B. Alexander G. C. (2020 ). Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. BMJ Open 10 (6), e039978.
Not in our library10.1136/bmjopen-2020-039978
283.
Mehtar S. Preiser P. Lakhe N. A. Bousso A. TamFum J.-J. M. Kallay O. (2020 ). Limiting the spread of COVID-19 in Africa: one size mitigation strategies do not fit all countries. Lancet Global Health. 8 (7), e881–e883.
Not in our library10.1016/s2214-109x(20)30212-6
284.
Mendelson M. Matsoso M. (2015 ). The South African Antimicrobial Resistance Strategy Framework. AMR Control, 54–61.
Not in our library
285.
Meng L. Qiu H. Wan L. Ai Y. Xue Z. Guo Q. (2020 ). Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience. Anesthesiology 132 (6), 1317–1332.
Not in our library10.1097/aln.0000000000003296
286.
Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: a systematic analysis of data from the Global Burden of Disease Study 2013: cardiovascular topic · 2015
No notice
287.
Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications · 2020
Not checked
288.
Mining Review (2020 ). South's Africa COVID-19 PPE shortage being addressed. Available at: https://www.miningreview.com/health-and-safety/souths-africa-covid-19-ppe-shortage-being-addressed/.
Not in our library
289.
Ministry of Communications, Republic of Ghana (2020 ). Launch of GH COVID-19 Tracker App. Available at: https://www.moc.gov.gh/launch-gh-covid-19-tracker-app.
Not in our library
290.
Ministry of Health, VietNam (2020 ). Hướng dẫn chẩn đoán và điều trị viêm đường hô hấp cấp do SARS-CoV-2 (COVID-19) phiên bản lần thứ 3. Available at: https://kcb.vn/huong-dan-chan-doan-va-dieu-tri-viem-duong-ho-hap-cap-do-sar-cov-2-covid-19-phien-ban-lan-thu-3.html.
Not in our library
291.
Mitjà O. Clotet B. (2020 ). Use of antiviral drugs to reduce COVID-19 transmission. Lancet Global Health 8 (5), e639–ee40.
Not in our library10.1016/s2214-109x(20)30114-5
292.
Modisakeng C. Matlala M. Godman B. Meyer J. C. (2020 ). Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications. BMC Health Serv. Res. 20 (1), 234.
Not in our library10.1186/s12913-020-05080-1
293.
Monteleone G. Sarzi-Puttini P. C. Ardizzone S. (2020 ). Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol. 2 (5), E255–E256.
Not in our library10.1016/s2665-9913(20)30092-8
294.
Moore W. G. (2020 ). Curfews are a safer plan than total lockdowns to slow Covid-19's spread in informal economies. Available at: https://qz.com/africa/1836458/curfews-not-lockdowns-will-slow-covid-19-spread-in-africa/.
Not in our library
295.
Policies for biosimilar uptake in Europe: An overview · 2017
No notice
296.
MSF (2019 ). A multidisciplinary approach to stem the spread of cholera. Available at: https://www.msf.org/how-stem-spread-cholera-cameroon-and-lake-chad-region.
Not in our library
297.
MSF (2020 ). Eswatini: Responding to COVID-19 in a country already fighting a dual HIV/TB epidemic. Available at: https://www.msf.org/responding-covid-19-eswatini.
Not in our library
298.
Mueller D. Tivey D. Croce D. (2017 ). Health-technology assessment: Its role in strengthening health systems in developing countries. South. Afr. J. Public Health 2 (1), 6–11.
Not in our library
299.
Mukokinya M. Opanga S. Oluka M. Godman B. (2018 ). Dispensing of antimicrobials in Kenya: A cross-sectional pilot study and its implications. J. Res. Pharm. Pract. 7 (2), 77–82.
Not in our library10.4103/jrpp.jrpp_17_88
300.
Mules I. (2020 ). Tanzania under fire from WHO for lackluster response to COVID-19 pandemic. Available at: https://www.dw.com/en/tanzania-under-fire-from-who-for-lackluster-response-to-covid-19-pandemic/a-53304699.
Not in our library
301.
Muraya J. (2020 ). Govt turns spotlight on refugee camps as COVID-19 hits 490 in Kenya. Available at: https://www.capitalfm.co.ke/news/2020/05/govt-turns-spotlight-on-refugee-camps-as-covid-19-hits-490-in-kenya/.
Not in our library
302.
Intensive Care Unit Capacity in Low-Income Countries: A Systematic Review · 2015
No notice
303.
Mutahi B. (2020 ). Coronavirus: The fear of being sentenced to a Kenyan quarantine centre. Available at: https://www.bbc.co.uk/news/world-africa-52326316.
Not in our library
304.
Mwai P. Giles C. (2020 ). Coronavirus in Tanzania: What do we know? Available at: https://www.bbc.co.uk/news/world-africa-52723594.
Not in our library
305.
N Gage Consulting (2017 ). Egypt's Pharmaceutical Sector Following Bold Economic Reforms: Challenges and Opportunities. Available at: https://www.ngage-consulting.com/downloads/Pharmaceutical_PDF_Final_Version_K_and_A.pdf.
Not in our library
306.
Nachimuthu S. Vijayalakshmi R. Sudha M. Viswanathan V. (2020 ). Coping with diabetes during the COVID - 19 lockdown in India: Results of an online pilot survey. Diabetes Metab. Syndrome 14 (4), 579–582.
Not in our library10.1016/j.dsx.2020.04.053
307.
Neil S. Campbell E. M. (2020 ). Fake Science: XMRV, COVID-19 And The Toxic Legacy of Dr Judy Mikovits. AIDS Res. Hum. Retrov. 36 (7), 545–549.
Not in our library10.1089/aid.2020.0095
308.
Newton P. N. Bond K. C. (2020 ). COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. Lancet Global Health. 8 (6), e754–e755.
Not in our library10.1016/s2214-109x(20)30136-4
309.
Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020 · 2020
No notice
310.
Nga L. Phuong L. Anh P. (2020 ). Hanoi man OD's on rumored malaria drug cure for Covid-19. 23 March 2020. Available at: https://e.vnexpress.net/news/news/hanoi-man-od-s-on-rumored-malaria-drug-cure-for-covid-19-4073488.html
Not in our library
311.
Nicholas T. Mandaah F. V. Esemu S. N. Vanessa A. B. T. Gilchrist K. T. D. Vanessa L. F. (2020 ). COVID-19 knowledge, attitudes and practices in a conflict affected area of the South West Region of Cameroon. PAMJ 35 (2), 34.
Not in our library10.11604/pamj.supp.2020.35.2.22963
312.
Nigeria CDC (2018 ). A home coming: My visit to Liberia's new National Public Health Institute. Available at: https://ncdc.gov.ng/blog/post/29/?t=a-home-coming:-my-visit-to-liberia%E2%80%99s-new-national-public-health-institute.
Not in our library
313.
Nigeria Centre for Disease Control (2020 a). Guidelines and Protocols - National Interim Guidelines for Clinical Management of COVID-19. Available at: https://ncdc.gov.ng/themes/common/docs/protocols/177_1584210847.pdf.
Not in our library
314.
Nigeria Centre for Disease Control (2020 b). An update of Lassa fever outbreak in Nigeria. Available at: https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria.
Not in our library
315.
NIH ClinicalTrials.gov (2020 a). BCG Vaccination for Healthcare Workers in COVID-19 Pandemic. Available at: https://clinicaltrials.gov/ct2/show/NCT04379336?cond=COVID-19&cntry=ZA&draw=2.
Not in our library
316.
NIH ClinicalTrials.gov (2020 b). COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection. Available at: https://clinicaltrials.gov/ct2/show/NCT04444674?cond=COVID-19&cntry=ZA&draw=2&rank=7.
Not in our library
317.
NIH (2020 a). The National Institutes of Health COVID-19 Treatment Guidelines Panel Provides Recommendations for Dexamethasone in Patients with COVID-19. 25 June 2020. Available at: https://www.covid19treatmentguidelines.nih.gov/dexamethasone/.
Not in our library
318.
NIH (2020 b). NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. 29 April 2020. Available at: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19.
Not in our library
319.
NIH (2020 c). NIH halts clinical trial of hydroxychloroquine. 20 June 2020. Available at: https://www.nhlbi.nih.gov/news/2020/nih-halts-clinical-trial-hydroxychloroquine.
Not in our library
320.
Nkeck J. R. Tsafack E. E. Ndoadoumgue A. L. Endomba F. T. (2020 ). An alert on the incautious use of herbal medicines by sub-Saharan African populations to fight against the COVID-19. PAMJ 35 (2), 26.
Not in our library10.11604/pamj.supp.2020.35.2.23161
321.
Nkengasong J. N. Mankoula W. (2020 ). Looming threat of COVID-19 infection in Africa: act collectively, and fast. Lancet 395 (10227), 841–842.
Not in our library10.1016/s0140-6736(20)30464-5
322.
Nordling N. (2020 ). Unproven herbal remedy against COVID-19 could fuel drug-resistant malaria, scientists warn. Available at: https://www.sciencemag.org/news/2020/05/unproven-herbal-remedy-against-covid-19-could-fuel-drug-resistant-malaria-scientists.
Not in our library
323.
Nussbaumer-Streit B. Mayr V. Dobrescu A. I. Chapman A. Persad E. Klerings I. (2020 ). Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst. Rev. 4, Cd013574.
Not in our library10.1002/14651858.cd013574
324.
Nyaira S. (2020 ). Ways Africa's Free Trade Area could help mitigate effects of COVID-19. Available at: https://www.un.org/africarenewal/web-features/coronavirus/ways-africa%E2%80%99s-free-trade-area-could-help-mitigate-effects-covid-19.
Not in our library
325.
Nyavor G. (2020 ). Breakthrough as Ghana researchers develop rapid diagnostic testing for Covid-19. Available at: https://www.myjoyonline.com/news/health/breakthrough-as-ghana-researchers-develop-rapid-diagnostic-testing-for-covid-19/.
Not in our library
326.
O'Neill L. A. J. Netea M. G. (2020 ). BCG-induced trained immunity: can it offer protection against COVID-19? Nat. Rev. Immunol. 20 (6), 335–337.
Not in our library10.1038/s41577-020-0337-y
327.
OCHA Zimbabwe (2020 ). Situation Reports Highlights. 7 May 2020. Available at: https://reliefweb.int/sites/reliefweb.int/files/resources/Situation%20Report%20-%20Zimbabwe%20-%206%20May%202020.pdf.
Not in our library
328.
OCHA (2020 ). Sudan Situation Report Updated. 19 March 2020. Available at: https://reliefweb.int/sites/reliefweb.int/files/resources/Situation%20Report%20-%20Sudan%20-%2019%20Mar%202020.pdf.
Not in our library
329.
OECD (2020 ). The Covid-19 Crisis in Egypt. Available at: https://www.oecd.org/mena/competitiveness/The-Covid-19-Crisis-in-Egypt.pdf.
Not in our library
330.
Okonjo-Iweala N. Coulibaly B. S. Thiam T. Kaberuka D. Songwe V. Masiyiwa S. (2020 ). Africa needs debt relief to fight COVID-19. Available at: https://www.brookings.edu/opinions/africa-needs-debt-relief-to-fight-covid-19/.
Not in our library
331.
Okwen P. M. Maweu I. Grimmer K. Margarita Dizon J. (2019 ). Evaluation of all African clinical practice guidelines for hypertension: Quality and opportunities for improvement. J. Eval. Clin. Pract. 25 (4), 565–574.
Not in our library10.1111/jep.12954
332.
Olafusi E. (2020 ). The World Health Organisation (WHO) says Nigeria has expressed interest to be part of the global solidarity drug trial to combat COVID-19. Available at: https://www.thecable.ng/who-nigeria-has-expressed-interest-to-be-part-of-covid-19-drug-trials.
Not in our library
333.
Ong S. E. Koh J. J. K. Toh S. E. S. Chia K. S. Balabanova D. McKee M. (2018 ). Assessing the influence of health systems on Type 2 Diabetes Mellitus awareness, treatment, adherence, and control: A systematic review. PLoS One 13 (3), e0195086.
Not in our library10.1371/journal.pone.0195086
334.
Ongole J. J. Rossouw T. M. Fourie P. B. Stoltz A. C. Hugo J. Marcus T. S. (2020 ). Sustaining essential healthcare in Africa during the COVID19 pandemic. Available at: https://www.theunion.org/news-centre/news/body/IJTLD-June-0214_Ongole.pdf.
Not in our library10.5588/ijtld.20.0214
335.
Patterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa- a cross sectional study · 2015
No notice
336.
Outbreak News (2020 ). Cameroon monkeypox: Follow-up and more details. Available at: http://outbreaknewstoday.com/cameroon-monkeypox-follow-up-and-more-details-15866/.
Not in our library
337.
Pan D. Sze S. Minhas J. S. Bangash M. N. Pareek N. Divall P. (2020 ). The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine 23, 100404.
Not in our library10.1016/j.eclinm.2020.100404
338.
Paranjpe I. Fuster V. Lala A. Russak A. Glicksberg B. S. Levin M. A. (2020 ). Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J. Am. Coll. Cardiol. 76 (1), 122–124.
Not in our library10.1016/j.jacc.2020.05.001
339.
Pareek M. Bangash M. N. Pareek N. Pan D. Sze S. Minhas J. S. (2020 ). Ethnicity and COVID-19: an urgent public health research priority. Lancet 395 (10234), 1421–1422.
Not in our library10.1016/s0140-6736(20)30922-3
340.
Effects of Response to 2014–2015 Ebola Outbreak on Deaths from Malaria, HIV/AIDS, and Tuberculosis, West Africa · 2016
No notice
341.
Pauloluniyi (2020 ). First African SARS-CoV-2 genome sequence from Nigerian COVID-19 case. Available at: http://virological.org/t/first-african-sars-cov-2-genome-sequence-from-nigerian-covid-19-case/421.
Not in our library
342.
Payne C. (2020 ). COVID-19 in Africa. Nat. Hum. Behav. 4 (5), 436–437.
Not in our library10.1038/s41562-020-0870-5
343.
Pearson J. Nguyen P. (2020 ). Vietnam to ease nationwide coronavirus lockdown. Available at: https://uk.reuters.com/article/uk-health-coronavirus-vietnam/vietnam-to-ease-nationwide-coronavirus-lockdown-idUKKCN2241LD.
Not in our library
344.
Perencevich E. N. Diekema D. J. Edmond M. B. (2020 ). Moving Personal Protective Equipment Into the Community: Face Shields and Containment of COVID-19. JAMA.
Not in our library10.1001/jama.2020.7477
345.
Perry Wilson F. (2020 ). COVID-19, Hydroxycloroquine, and the Death of Evidence-Based Medicine. Available at: https://www.methodsman.com/blog/covid-19-evidence.
Not in our library
346.
Phiri C. (2020 ). African Countries Urged To Collaborate More In The Fight Against Covid-19. Available at: https://zambiareports.com/2020/04/30/african-countries-urged-collaborate-fight-covid-19/.
Not in our library
347.
Pilling D. (2020 ). Low Covid-19 death toll raises hopes Africa may be spared worst. Available at: https://www.ft.com/content/e9cf5ed0-a590-4bd6-8c00-b41d0c4ae6e0.
Not in our library
348.
Pitts P. J. (2019 ). Towards Meaningful Engagement for the Patient Voice. Patient - Patient-Centered Outc. Res. 12 (4), 361–363.
Not in our library10.1007/s40271-019-00366-x
349.
Pitts P. J. (2020 ). Our Most Powerful Weapon to Fight COVID-19: Patient Involvement. Patient - Patient-Centered Outc. Res. 13 (3), 255.
Not in our library10.1007/s40271-020-00421-y
350.
Politi D. (2020 ). Nigeria Reports Chloroquine Poisonings as Trump Keeps Pushing Drug Against Coronavirus. Available at: https://slate.com/news-and-politics/2020/03/nigeria-chloroquine-poisonings-trump-pushing-drug-coronavirus.html.
Not in our library
351.
Pradhan D. Biswasroy P. Kumar Naik P. Ghosh G. Rath G. (2020 ). A Review of Current Interventions for COVID-19 Prevention. Arch. Med. Res. 51 (5), 363–374.
Not in our library10.1016/j.arcmed.2020.04.020
352.
President Republic of Kenya (2020 a). Africa To Pursue Loan Waivers As Safeguard Against Adverse Economic Impact Of Coronavirus. Available at: https://www.president.go.ke/2020/04/04/africa-to-pursue-loan-waivers-as-safeguard-against-adverse-economic-impact-of-coronavirus/.
Not in our library
353.
President Republic of Kenya (2020 b)Presidential Address on The State Interventions to Cushion Kenyans Against Economic Effects Of Covid-19 Pandemic on 25th March, 2020. Available at: https://www.president.go.ke/2020/03/25/presidential-address-on-the-state-interventions-to-cushion-kenyans-against-economic-effects-of-covid-19-pandemic-on-25th-march-2020/.
Not in our library
354.
Prokunina-Olsson L. Alphonse N. Dickenson R. E. Durbin J. E. Glenn J. S. Hartmann R. (2020 ). COVID-19 and emerging viral infections: The case for interferon lambda. J. Exp. Med. 217 (5), 1–4.
Not in our library10.1084/jem.20200653
355.
Public Health England (2020 ). Disparities in the risk and outcomes of COVID-19. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/892085/disparities_review.pdf.
Not in our library
356.
Rajendran D. K. Rajagopal V. Alagumanian S. Santhosh Kumar T. Sathiya Prabhakaran S. P. Kasilingam D. (2020 ). Systematic literature review on novel corona virus SARS-CoV-2: a threat to human era. VirusDisease 31 (2), 161–173.
Not in our library10.1007/s13337-020-00604-z
357.
Rajkumar R. P. (2020 ). COVID-19 and mental health: A review of the existing literature. Asian J. Psychiatry 52, 102066.
Not in our library10.1016/j.ajp.2020.102066
358.
Ramalingam S. Graham C. Dove J. Morrice L. Sheikh A. (2019 ). A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci. Rep. 9 (1), 1015.
Not in our library10.1038/s41598-018-37703-3
359.
Ramalingam S. Graham C. Dove J. Morrice L. Sheikh A. (2020 ). Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19. J. Global Health 10 (1), 010332.
Not in our library10.7189/jogh.10.010332
360.
Reade M. C. Finfer S. (2014 ). Sedation and delirium in the intensive care unit. N Engl. J. Med. 370 (5), 444–454.
Not in our library10.1056/nejmra1208705
361.
Recovery Collaborative GroupHorby P. Lim W.S. Emberson Mafham M. JR Bell J.L. Linsell L. (2020 ). Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med.
Not in our library10.1056/nejmoa2021436
362.
Recovery Trial (2020 a). No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Available at: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.
Not in our library
363.
Recovery Trial (2020 b). Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir, 29 June 2020. No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY. Available at: https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf.
Not in our library
364.
Recovery Trial (2020 a). No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Available at: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.
Not in our library
365.
Rees V. Dexamethasone to be available on NHS as COVID-19 treatment. 22 June 2020. Available at: https://www.europeanpharmaceuticalreview.com/news/121560/dexamethasone-to-be-available-on-nhs-as-covid-19-treatment/
Not in our library
366.
ReliefWeb (2020 a). Democratic Republic of Congo: Coronavirus (COVID-19) Situation Report 5. Available at: https://reliefweb.int/report/democratic-republic-congo/democratic-republic-congo-coronavirus-covid-19-situation-report-5.
Not in our library
367.
ReliefWeb (2020 b). Namibia launches COVID-19 Communication Centre. Available at: https://reliefweb.int/report/namibia/namibia-launches-covid-19-communication-centre.
Not in our library
368.
Ren Y. Zhou Y. Qian W. Zhang X. Liu Z. Wang R. (2020 ). Letter to the Editor “A longitudinal study on the mental health of general population during the COVID-19 epidemic in China”. Brain Behav. Immun. 87, 132–133.
Not in our library10.1016/j.bbi.2020.05.004
369.
Republic of South Africa Government Gazette (2020 ). Exclusion Of Schedule 2, Schedule 3 And Schedule 4 Substances From The Operation Of Certain Provisions Of The Medicines And Related Substances Act, 1965 (Act No. 101 of 1965). April 2020. Available at: https://edit.laws.africa/works/akn/za/act/gn/2020/r481/media/publication/za-act-gn-2020-r481-publication-document.pdf.
Not in our library
370.
Review Online (2020 ). No lithium tablets: anti-depressant shortage looms. Available at: https://reviewonline.co.za/404809/no-lithium-tablets-anti-depressant-shortage-looms/.
Not in our library
371.
Rich D. (2020 ). Covid-19: In Cameroon, chloroquine therapy hailed by French expert becomes state protocol. Available at: https://www.france24.com/en/20200503-covid-19-in-cameroon-a-chloroquine-therapy-hailed-by-french-expert-becomes-state-protocol.
Not in our library
372.
Richardson S. Hirsch J. S. Narasimhan M. Crawford J. M. McGinn T. Davidson K. W. (2020 ). Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323 (20), 2052–2059.
Not in our library10.1001/jama.2020.6775
373.
Rios-González C. M. (2020 ). Knowledge, attitudes and practices towards COVID-19 in Paraguayans during outbreaks: a quick online survey. Available at: https://preprints.scielo.org/index.php/scielo/preprint/download/149/179/164
Not in our library
374.
Roberto M. (2020 ). Testing COVID-19 costs KSh 100 in Senegal while Kenyan hospital charges KSh 10k for same service. Available at: https://www.msn.com/en-xl/news/other/testing-covid-19-costs-ksh-100-in-senegal-while-kenyan-hospital-charges-ksh-10k-for-same-service/ar-BB13gPE3.
Not in our library
375.
Rosenberg E. S. Dufort E. M. Udo T. Wilberschied L. A. Kumar J. Tesoriero J. (2020 ). Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 323 (24), 2493–2502.
Not in our library10.1001/jama.2020.8630
376.
Roumier M. Paule R. Groh M. Vallee A. Ackermann F. (2020 ). Interleukin-6 blockade for severe COVID-19. medrxiv 04 (20), 20061861.
Not in our library
377.
Roussi A. Maxmen A. (2020 ). African nations missing from coronavirus trials. Nature.
Not in our library10.1038/d41586-020-01010-7
378.
Rubin E. J. Harrington D. P. Hogan J. W. Gatsonis C. Baden L. R. Hamel M. B. (2020 ). The Urgency of Care during the Covid-19 Pandemic - Learning as We Go. N Engl. J. Med. 382 (25), 2461–2462.
Not in our library10.1056/nejme2015903
379.
Ryan D. H. Ravussin E. Heymsfield S. (2020 ). COVID 19 and the Patient with Obesity - The Editors Speak Out. Obesity 28 (5), 847.
Not in our library10.1002/oby.22808
380.
Saba A. Jika T. (2020 ). Eastern Cape's PPE shortage endangers healthcare workers. Available at: https://mg.co.za/article/2020-04-23-eastern-capes-ppe-shortage-endangers-healthcare-workers/
Not in our library
381.
SADC (2020 ). Statement by the SADC Executive Secretary, H.E. Dr Stergomena Lawrence Tax on Covid-19 and Gender Based Violence and Domestic Violence. Available at: https://www.sadc.int/news-events/news/statement-sadc-executive-secretary-he-dr-stergomena-lawrence-tax-covid-19-and-gender-based-violence-and-domestic-violence/.
Not in our library
382.
SAHPRA (2020 a). SAHPRA cautions against medicine stockpiling including Chloroquine containing products. Available at: http://www.sahpra.org.za/wp-content/uploads/2020/03/SAHPRA-communique_Chloroquine-Stockpiling_23032020.pdf.
Not in our library
383.
SAHPRA (2020 b). SAHPRA STATEMENT: BCG Vaccination and COVID-19 Disease. Available at: http://www.sahpra.org.za/wp-content/uploads/2020/04/SAHPRA-STATEMENT_BCGVaccinations-and-COVID-19.pdf.
Not in our library
384.
Saleem Z. Godman B. Hassali M. A. Hashmi F. K. Azhar F. Rehman I. U. (2019 ). Point prevalence surveys of health-care-associated infections: a systematic review. Pathog. Global Health 1–15.
Not in our library10.1080/20477724.2019.1632070
385.
Salum G. A. Rehmenklau J. F. Csordas M. C. Pereira F. P. Castan J. U. Ferreira A. B. (2020 ). Supporting people with severe mental health conditions during the COVID-19 pandemic: considerations for low- and middle-income countries using telehealth case management. Rev. Bras. Psiquiatria.
Not in our library10.1590/1516-4446-2020-1078
386.
Sanders J. M. Monogue M. L. Jodlowski T. Z. Cutrell J. B. (2020 ). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA.
Not in our library10.1001/jama.2020.6019
387.
SAMRC (2020 ). COVID-19 research - Systematic Reviews to inform Public Health Guidance on COVID-19. Available at: https://www.samrc.ac.za/intramural-research-units/covid-19-research.
Not in our library
388.
SAPC (2020 ). South African Pharmacy Council discourages panic-fuelled bulk purchases of essential supplies and medicinal items amid the coronavirus outbreak. Media Statement. 22 March 2020. Available at: https://www.sapc.za.org/Media/Default/Documents/SAPC%20Media%20Statement_Panic-fueled%20purchases.pdf.
Not in our library
389.
Sarma P. Kaur H. Kumar H. Mahendru D. Avti P. Bhattacharyya A. (2020 ). Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J. Med. Virol. 92 (7), 776–785.
Not in our library10.1002/jmv.25898
390.
Scavone C. Brusco S. Bertini M. Sportiello L. Rafaniello C. Zoccoli A. (2020 ). Current pharmacological treatments for COVID-19: what's next? Br. J. Pharmacol.
Not in our library10.1111/bph.15072
391.
Schaaf H. S. du Preez K. Kruger M. Solomons R. Taljaard J. J. Rabie H. (2020 ). Bacille Calmette-Guérin (BCG) vaccine and the COVID-19 pandemic: responsible stewardship is needed. Available at: https://www.theunion.org/news-centre/news/body/IJTLD-0267_Schaaf.pdf.
Not in our library10.5588/ijtld.20.0267
392.
Schellack N. Bronkhorst E. Coetzee R. Godman B. Gous A. G. S. Kolman S. (2018 ). SASOCP position statement on the pharmacist's role in antibiotic stewardship 2018. South Afr. J. Infect. Dis. 33 (1), 28–35.
Not in our library
393.
School of Public Health Makerere University (2020 ). Inside the Makerere Covid-19 Innovation activities. Available at: https://sph.mak.ac.ug/news/inside-makerere-covid-19-innovation-activities.
Not in our library
394.
Schroder M. Bossert A. Kersting M. Aeffner S. Coetzee J. Timme M. (2020 ). COVID-19 in Africa: outbreak despite interventions? MedRxiv preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.04.24.20077891v1.full.pdf.
Not in our library10.1101/2020.04.24.20077891.t
395.
Sciama Y. (2020 ). Is France's president fueling the hype over an unproven coronavirus treatment? Available at: https://www.sciencemag.org/news/2020/04/france-s-president-fueling-hype-over-unproven-coronavirus-treatment.
Not in our library
396.
Seaton A. (2020 ). COVID-19 and its impact on antimicrobial stewardship. Available at: https://revive.gardp.org/covid-19-and-its-impact-on-antimicrobial-stewardship/.
Not in our library
397.
Serwornoo M. Abrokwah R. (2020 ). Ghana: Coronavirus and the media. Available at: https://en.ejo.ch/ethics-quality/ghana-coronavirus-and-the-media.
Not in our library
398.
Shah M. Sachdeva M. Dodiuk-Gad R. P. (2020 ). COVID-19 and Racial Disparities. J. Am. Acad. Dermatol.
Not in our library10.1016/j.jaad.2020.04.046
399.
Shalhoub S. (2020 ). Interferon beta-1b for COVID-19. Lancet 395 (10238), 1670–1671.
Not in our library10.1016/s0140-6736(20)31101-6
400.
Shepherd B. van der Mark N. (2020 ). Beyond Lockdown: Africa's Options for Responding to COVID-19. Available at: https://www.chathamhouse.org/expert/comment/beyond-lockdown-africa-s-options-responding-covid-19.
Not in our library
401.
Shi C. Wang C. Wang H. Yang C. Cai F. Zeng F. (2020 ). Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study. medrxiv.
Not in our library10.1101/2020.03.28.20046144
402.
Simpson B. W. (2020 ). In COVID-19, the Africa CDC Faces Its Greatest Challenge. Available at: https://www.globalhealthnow.org/2020-03/covid-19-3-year-old-africa-cdc-faces-its-greatest-challenge.
Not in our library
403.
Singh D. R. Sunuwar D. R. Karki K. Ghimire S. Shrestha N. (2020 a). Knowledge and Perception Towards Universal Safety Precautions During Early Phase of the COVID-19 Outbreak in Nepal. J. Community Health, 1–7.
Not in our library10.1007/s10900-020-00839-3
404.
Singh A. K. Singh A. Singh R. Misra A. (2020 b). Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis. Diabetes Metab. Syndrome 14 (4), 589–596.
Not in our library10.1016/j.dsx.2020.05.017
405.
Smith G. (2020 ). Stamping out misinformation in Kenya's COVID-19 fight - Volunteers and activists work to diffuse spread of fake information, false 'remedies' as Kenya steps up pandemic battle. Available at: https://www.aljazeera.com/news/2020/04/stamping-misinformation-kenya-covid-19-fight-200424195805081.html.
Not in our library
406.
So-Armah K. Freiberg M. S. (2018 ). HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers. Curr. HIV/AIDS Rep. 15 (3), 233–244.
Not in our library10.1007/s11904-018-0400-5
407.
South African Government (2020 a). President Ramaphosa launches the Africa Medical Supplies Platform to help fight COVID-19 Coronavirus Pandemic. Available at: https://www.gov.za/speeches/president-ramaphosa-launches-africa-medical-supplies-platform-help-fight-covid-19.
Not in our library
408.
South African Government (2020 b). Regulations and Guidelines - Coronavirus Covid-19. Available at: https://www.gov.za/coronavirus/guidelines.
Not in our library
409.
South African Government (2020 c). President Cyril Ramaphosa: Additional Coronavirus COVID-19 economic and social relief measures. 21 April 2020. Available at: https://www.gov.za/speeches/president-cyril-ramaphosa-additional-coronavirus-covid-19-economic-and-social-relief.
Not in our library
410.
South African Government (2020 d). Social grants - Coronavirus COVID-19. Available at: https://www.gov.za/coronavirus/socialgrants.
Not in our library
411.
Southern African Health Technology Assessment Society (SAHTAS) (2019 ). http://www.htasa.org.za/.
Not in our library
412.
Sterne J. A. C. Murthy S. Diaz J. V. Slutsky A. S. Villar J. Angus D. (2020 ). Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. Jama (EPrint).
Not in our library10.1001/jama.2020.17023
413.
Takyi-Boadu C. (2020 ). Government Officials Donate 3 months Salaries to Help Fight Covid-19. Available at: https://dailyguidenetwork.com/government-officials-donate-3months-salaries-to-help-fight-covid-19/.
Not in our library
414.
Tamam L. Yerdelen D. Ozpoyraz N. (2003 ). Psychosis associated with interferon alfa therapy for chronic hepatitis B. Ann. Pharmacother. 37 (3), 384–387.
Not in our library10.1345/aph.1c266
415.
Tang N. Bai H. Chen X. Gong J. Li D. Sun Z. (2020 ). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemostasis 18 (5), 1094–1099.
Not in our library10.1111/jth.14817
416.
Tarkang E. E. (2020 ). The fight against COVID-19 in sub-Saharan Africa-a threat to the continuous management of HIV patients: application of the action areas of the Ottawa charter for health promotion. PAMJ 35 (2), 25.
Not in our library10.11604/pamj.supp.2020.35.2.23224
417.
Tembo L. (2020 ). Coping with school closures during the COVID-19 pandemic - Keeping children learning is a priority. Available at: https://www.unicef.org/malawi/stories/coping-school-closures-during-covid-19-pandemic.
Not in our library
418.
Thai P. Q. Rabaa M. A. Luong D. H. Tan D. Q. Quang T. D. Quach H.-L. (2020 ). The first 100 days of SARS-CoV-2 control in Vietnam. Clin Infect. Dis.
Not in our library10.1093/cid/ciaa1130
419.
The East African (2020 ). Seven die, 134 treated after cholera outbreak in northern Kenya. Available at: https://www.theeastafrican.co.ke/scienceandhealth/Cholera-kills-7-in-northern-Kenya/3073694-5538830-c21ggo/index.html.
Not in our library
420.
The Guardian (2020 a). High hopes' drug for Covid-19 treatment failed in full trial. April 2020. Available at: https://www.msn.com/en-gb/news/coronavirus/high-hopes-drug-for-covid-19-treatment-failed-in-full-trial/ar-BB136z6g?ocid=spartandhp.
Not in our library
421.
The Guardian (2020 b). Coronavirus: world's biggest trial of drug to treat Covid-19 begins in UK. Available at: https://www.theguardian.com/world/2020/apr/17/world-biggest-drug-trial-covid-19-uk.
Not in our library
422.
The Lancet Editorial (2020 ). Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (London England) 395 (10240), e102–e10e.
Not in our library10.1016/s0140-6736(20)31290-3
423.
The Reportor (2020 ). Lesotho now doing own COVID-19 testing. 26 June 2020. Available at: https://www.pressreader.com/lesotho/the-reporter/20200626/281500753517045.
Not in our library
424.
The World Bank (2020 a). World Bank Group Supports Ghana's COVID-19 Response. Available at: https://www.worldbank.org/en/news/press-release/2020/04/02/world-bank-group-supports-ghanas-covid-19-response.
Not in our library
425.
The World Bank (2020 b). Kenya Receives $50 Million World Bank Group Support to Address COVID-19 Pandemic. Available at: https://www.worldbank.org/en/news/press-release/2020/04/02/kenya-receives-50-million-world-bank-group-support-to-address-covid-19-pandemic.
Not in our library
426.
Thornicroft G. Rose D. Kassam A. Sartorius N. (2007 ). Stigma: ignorance, prejudice or discrimination? Br. J. Psychiatry J. Ment. sci. 190, 192–193.
Not in our library10.1192/bjp.bp.106.025791
427.
Thornton J. (2020 ). Covid-19: Keep essential malaria services going during pandemic, urges WHO. BMJ 369, m1637.
Not in our library10.1136/bmj.m1637
428.
Tih F. (2020 ). African countries ease COVID-19 lockdown restrictions - Governments say there is need to resume economic activities with imperative to contain virus. Available at: https://www.aa.com.tr/en/africa/african-countries-ease-covid-19-lockdown-restrictions/1827900.
Not in our library
429.
Tilangi P. Desai D. Khan A. Soneja M. (2020 ). Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. Lancet Infect. Dis.
Not in our library10.1016/s1473-3099(20)30430-8
430.
Times of Swaziland (2020 ). Over 100 Companies to Lay Off Staff. Available at: http://www.times.co.sz/news/127933-over-100-companies-to-lay-off-staff.html.
Not in our library
431.
Tomlinson C. (2020 ). Covid-19: Is South Africa prepared for medicine shortages? (City Press). Available at: https://city-press.news24.com/News/covid-19-is-south-africa-prepared-for-medicine-shortages-20200316-2.
Not in our library
432.
Tomazini B. M. Maia I. S. Cavalcanti A. B. Berwanger O. Rosa R. G. Veiga V. C. (2020 ). Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. Jama (EPrint).
Not in our library10.1001/jama.2020.17021
433.
Toniati P. Piva S. Cattalini M. Garrafa E. Regola F. Castelli F. (2020 ). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun. Rev. 19 (7), 102568.
Not in our library10.1016/j.autrev.2020.102568
434.
TradingEconomics (2020 ). Swaziland Interest Rate. Available at: https://tradingeconomics.com/swaziland/interest-rate.
Not in our library
435.
A Review of SARS-CoV-2 and the Ongoing Clinical Trials · 2020
No notice
436.
UK Department of Health and Social Care (2020 ). Clinical trial approved to help the NHS treat COVID-19 patients using plasma. April 2020. Available at: https://www.gov.uk/government/news/clinical-trial-approved-to-help-the-nhs-treat-covid-19-patients-using-plasma.
Not in our library
437.
UK Medicines & Healthcare Products Regulatory Agency EAMS 11972/0001 Remdesivir 100 mg powder for concentrate for solution for infusion. May 2020. Available at: https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-remdesivir-in-the-treatment-of-patients-hospitalised-with-suspected-or-laboratory-confirme/treatment-protocol-for-healthcare-professionals_eams-119720001-remdesivir-100-mg-powder-for-concentrate-for-solution-for-infusion.
Not in our library
438.
UN News (2020 ). Vaccine bottlenecks from COVID lockdown put children's lives at stake: UNICEF. Available at: https://news.un.org/en/story/2020/05/1063002.
Not in our library
439.
UNAIDS (2019 ) Global HIV & AIDS statistics — 2019 fact sheet. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.
Not in our library
440.
Ung C. O. L. (2020 ). Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak. Res. Soc. Adm. Pharm. 16 (4), 583–586.
Not in our library10.1016/j.sapharm.2020.02.003
441.
UNHCR (2020 ). Across West Africa dual challenge of conflict and coronavirus threatens millions of people. Available at: https://www.unhcr.org/uk/news/latest/2020/4/5e99b5074/across-west-africa-dual-challenge-conflict-coronavirus-threatens-millions.html.
Not in our library
442.
UNICEF Malawi (2020 ) UNICEF Malawi Supply Update on Coronavirus Disease (COVID-19) Response - Prepositioned and locally procured supplies provide critical input to Malawi response in combating COVID-19. Available at: https://www.unicef.org/malawi/coronavirus-disease-covid-19/unicef-malawi-supply-update-coronavirus-disease-covid-19-response.
Not in our library
443.
UNICEF South Africa (2020 ). Immunization against vaccine-preventable diseases is essential to protect children African Vaccination Week 2020 focuses on the importance of immunization in a time of COVID-19. Available at: https://www.unicef.org/southafrica/stories/immunization-against-vaccine-preventable-diseases-essential-protect-children.
Not in our library
444.
UNICEF (2020 ). COVID-19: Gavi and UNICEF to secure equipment and diagnostics for lower-income countries. Available at: https://www.unicef.org/press-releases/covid-19-gavi-and-unicef-secure-equipment-and-diagnostics-lower-income-countries.
Not in our library
445.
United Nations Africa Renewal (2020 ) Coronavirus Updates and Resources. 7 May 2020. Available at: https://www.un.org/africarenewal/news/coronavirus/new-who-estimates-190-000-people-could-die-covid-19-africa-if-not-controlled.
Not in our library
446.
United Nations Economic Commission for Africa (2020 a). UN sets up regional knowledge hub to fight COVID-19. Available at: https://www.uneca.org/stories/un-sets-regional-knowledge-hub-fight-covid-19.
Not in our library
447.
United Nations Economic Commission for Africa (2020 b). COVID-19 in Africa: Protecting Lives and Economies. Available at: https://www.uneca.org/sites/default/files/PublicationFiles/eca_covid_report_en_24apr_web1.pdf.
Not in our library
448.
United Nations Malawi (2020 ). COVID-19 Update. Available at: https://reliefweb.int/sites/reliefweb.int/files/resources/Malawi-COVID-19-Situation-Update-03.04.20.pdf.
Not in our library
449.
United Nations (2020 a). Policy Brief: COVID-19 and the Need for Action on Mental Health. Available at: https://www.un.org/sites/un2.un.org/files/un_policy_brief-covid_and_mental_health_final.pdf.
Not in our library
450.
United Nations (2020 b). Policy Brief: Impact of COVID-19 in Africa. Available at: https://www.un.org/sites/un2.un.org/files/sg_policy_brief_on_covid-19_impact_on_africa_may_2020.pdf.
Not in our library
451.
University of Ghana News Release (2020 ). University of Ghana (UG) Scientists Sequence Genomes of Novel Coronavirus. Available at: https://www.ug.edu.gh/news/news-release-university-ghana-scientists-sequence-genomes-novel-coronavirus.
Not in our library
452.
University of Nairobi (2020 ). UoN Ventilators, ready for production model. Available at: https://www.uonbi.ac.ke/news/uon-ventilators-ready-production-model.
Not in our library
453.
US Food and Drug Administration (2020 ). Emergency Use Authorization (EUA) for emergency use of remdesivir for the treatment of hospitalized coronavirus disease (COVID-19) patients. Available at: https://www.fda.gov/media/137564/download.
Not in our library
454.
US National Library of Medicine - ClinicalTrials.gov (2020 a). Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19. Available at: https://clinicaltrials.gov/ct2/show/NCT04347538.
Not in our library
455.
US National Library of Medicine - ClinicalTrials.gov (2020 b). Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19. Available at: https://clinicaltrials.gov/ct2/show/NCT04344236.
Not in our library
456.
US National Library of Medicine (2020 ). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results?cond=COVID-19&cntry=EG&age_v=&gndr=&type=Intr&rslt=&Search=Apply.
Not in our library
457.
van den Heever A. (2020 ). Projections on SA health system and whether there are enough hospital beds to cope. Available at: https://www.dailymaverick.co.za/article/2020-03-16-projections-on-sa-health-system-and-whether-there-enough-hospital-beds-to-cope/.
Not in our library
458.
COVID-19 and smoking: A systematic review of the evidence · 2020
No notice
459.
Vella Bonanno P. Bucsics A. Simoens S. Martin A. P. Oortwijn W. Gulbinovic J. (2019 ). Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. Expert Rev. Pharmacoecon. Outc. Res. 19 (3), 251–261.
Not in our library10.1080/14737167.2019.1575730
460.
Vellingiri B. Jayaramayya K. Iyer M. Narayanasamy A. Govindasamy V. Giridharan B. (2020 ). COVID-19: A promising cure for the global panic. Sci. Total Environ. 725, 138277.
Not in our library10.1016/j.scitotenv.2020.138277
461.
Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China · 2020
No notice
462.
Wang C. Pan R. Wan X. Tan Y. Xu L. McIntyre R. S. (2020 b). A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain Behav. Immun. 87, 40–48.
Not in our library10.1016/j.bbi.2020.04.028
463.
Wang C. J. Ng C. Y. Brook R. H. (2020 ). Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. JAMA.
Not in our library10.1001/jama.2020.3151
464.
Wang Y. Zhang D. Du G. Du R. Zhao J. Jin Y. (2020 ). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395 (10236), 1569–1578.
Not in our library10.1016/s0140-6736(20)31022-9
465.
Warrington T. P. Bostwick J. M. (2006 ). Psychiatric adverse effects of corticosteroids. Mayo Clin. Proc. 81 (10), 1361–1367.
Not in our library10.4065/81.10.1361
466.
Webster P. (2020 ). Virtual health care in the era of COVID-19. Lancet 395 (10231), 1180–1181.
Not in our library10.1016/s0140-6736(20)30818-7
467.
WHO Regional Office Africa (2020 a). COVID-19 - Situation Update for the WHO African Region - 1 July 2020. External Situation Report 18. Available at: https://apps.who.int/iris/bitstream/handle/10665/332929/SITREP_COVID-19_WHOAFRO_20200701-eng.pdf.
Not in our library
468.
WHO Regional Office Africa (2020 b). COVID-19 in the WHO African Region. Available at: https://www.afro.who.int/health-topics/coronavirus-covid-19.
Not in our library
469.
WHO Regional Office Africa (2020 c). African countries move from COVID-19 readiness to response as many confirm cases. 29 April 2020. Available at: https://www.afro.who.int/health-topics/coronavirus-covid-19.
Not in our library
470.
WHO Regional Office Africa (2020 d). COVID-19 - External Situation Report 9. 29 April 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/331935/SITREP_COVID-19_WHOAFRO_20200429-eng.pdf.
Not in our library
471.
WHO Coronavirus disease (COVID-19) Situation Report – 151. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200619-covid-19-sitrep-151.pdf?sfvrsn=8b23b56e_2.
Not in our library
472.
WHO (2019 a). Global Tuberculosis Report Executive Summary. Available at: https://www.who.int/tb/publications/global_report/tb19_Exec_Sum_15October2019.pdf?ua=1.
Not in our library
473.
WHO (2019 b). Global Tuberculosis Report (Full). Available at: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1.
Not in our library
474.
WHO (2019 c) World Malaria Report 2019. Available at: https://www.who.int/publications-detail/world-malaria-report-2019.
Not in our library
475.
WHO (2020 a). Coronavirus disease (COVID-19) Situation Report – 163. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701-covid-19-sitrep-163.pdf?sfvrsn=c202f05b_2.
Not in our library
476.
WHO (2020 b). Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Available at: https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations.
Not in our library
477.
WHO (2020 c) COVID-19 Strategy update. Available at: https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba.
Not in our library
478.
WHO (2020 d). COVID-19 Strategic Preparedness and Response Plan - OPERATIONAL PLANNING GUIDELINES TO SUPPORT COUNTRY PREPAREDNESS AND RESPONSE. Available at: https://www.who.int/docs/default-source/coronaviruse/covid-19-sprp-unct-guidelines.pdf.
Not in our library
479.
WHO (2020 e). WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. 4 July 2020. Available at: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19.
Not in our library
480.
WHO (2020 f). Bacille Calmette-Guérin (BCG) vaccination and COVID-19 - Scientific Brief. Available at: https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19.
Not in our library
481.
WHO (2020 g). Mental health and psychosocial considerations during the COVID-19 outbreak. Available at: https://www.who.int/publications-detail/WHO-2019-nCoV-MentalHealth-2020.1.
Not in our library
482.
WHO (2020 h) WHO Director-General's opening remarks at the media briefing on COVID-19 - 25 May 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—25-may-2020.
Not in our library
483.
WHO (2020 i). Emergency Ministerial meeting on COVID-19 organized by the African Union and the Africa Centres for Disease Control and Prevention. Available at: https://www.who.int/dg/speeches/detail/emergency-ministerial-meeting-on-covid-19-organized-by-the-african-union-and-the-africa-centres-for-disease-control-and-prevention.
Not in our library
484.
WHO (2020 j). Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Not in our library
485.
WHO (2020 k). Launch of the Lomé Initiative. Available at: https://www.who.int/dg/speeches/detail/launch-of-the-lom%C3%A9-initiative.
Not in our library
486.
WHO (2020 l). “Solidarity” clinical trial for COVID-19 treatments. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.
Not in our library
487.
WHO (2020 m). Ebola virus disease – Democratic Republic of the Congo. Available at: https://www.who.int/csr/don/23-April-2020-ebola-drc/en/.
Not in our library
488.
WHO (2020 n). Protecting lifesaving immunization services during COVID-19: New guidance from WHO. Available at: https://www.who.int/immunization/news_guidance_immunization_services_during_COVID-19/en/.
Not in our library
489.
Wilkinson L. Grimsrud A. (2020 ). The time is now: expedited HIV differentiated service delivery during the COVID-19 pandemic. J. Int. AIDS Soc. 23, e25503.
Not in our library10.1002/jia2.25503
490.
Williams F. M. K. Freidin M. B. Mangino M. Couvreur S. Visconti A. Bowyer R. C. E. (2020 ). Self-reported symptoms of covid-19 including symptoms most predictive of SARS-CoV2 infection, are heritable. MedRxiv preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.04.22.20072124v2.full.pdf.
Not in our library10.1101/2020.04.22.20072124
491.
Wits University (2020 a) The first Covid-19 vaccine trial in South Africa begins. 23 June 2020. Available at: https://www.wits.ac.za/covid19/covid19-news/latest/the-first-covid-19-vaccine-trial-in-south-africa-begins.html.
Not in our library
492.
Wits University (2020 b). Wits engineers make face shields to protect healthcare workers. Available at: https://www.wits.ac.za/covid19/covid19-news/latest/wits-engineers-make-face-shields-to-protect-healthcare-workers.html.
Not in our library
493.
Woldesemayat E. M. (2020 ). Chronic Diseases Multimorbidity among Adult People Living with HIV at Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia. Int. J. Chronic Dis. 2020, 2190395.
Not in our library10.1155/2020/2190395
494.
World Bank (2020 ). South Sudan: World Bank Provides $7.6 Million in Support of Coronavirus Emergency Response. Available at: https://www.worldbank.org/en/news/press-release/2020/04/09/south-sudan-world-bank-provides-76-million-in-support-of-coronavirus-emergency-response.
Not in our library
495.
World Food Programme (2020 ). COVID-19 will double number of people facing food crises unless swift action is taken. Available at: https://www.wfp.org/news/covid-19-will-double-number-people-facing-food-crises-unless-swift-action-taken.
Not in our library
496.
World Health Organisation Europe (2020 ) Health Systems Respond to COVID-19 Technical Guidance 2 - Creating surge capacity for acute and intensive care - Recommendations for the WHO European Region. Available at: http://www.euro.who.int/:data/assets/pdf_file/0006/437469/TG2-CreatingSurgeAcuteICUcapacity-eng.pdf.
Not in our library
497.
World Health Organisation (2019 ). Global Health Observatory data repository. Number of people (all ages) living with HIV - Estimates by WHO region. Available at: https://apps.who.int/gho/data/view.main.22100WHO?lang=en.
Not in our library
498.
World Health Organisation (2020 a). Naming the coronavirus disease (COVID-19) and the virus that causes it. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
Not in our library
499.
World Health Organisation (2020 b). Operational considerations for case management of COVID-19 in health facility and community: interim guidance, 19 March 2020. Available at: https://apps.who.int/iris/handle/10665/331492.
Not in our library
500.
World Health Organisation (2020 c). The potential impact of health service disruptions on the burden of malaria: a modelling analysis for countries in sub-Saharan Africa. Available at: https://apps.who.int/iris/bitstream/handle/10665/331845/9789240004641-eng.pdf?sequence=1&isAllowed=y.
Not in our library
501.
World Health Organization (2020 d) Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Available at: https://apps.who.int/iris/handle/10665/331590.
Not in our library
502.
World Health Organisation (2020 e). Medical Product Alert N°4/2020 - Falsified chloroquine products circulating in the WHO region of Africa. Available at: https://www.who.int/docs/default-source/essential-medicines/drug-alerts20/drug-alert-4/n-4-2020-falsified-chloroquine-en.pdf?sfvrsn=c4354802_6.
Not in our library
503.
World Health Organisation (2020 f). Coronavirus disease (COVID-19) advice for the public: Myth busters. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters.
Not in our library
504.
Worldometer (2020 ). African Countries by population. Available at: https://www.worldometers.info/population/countries-in-africa-by-population/.
Not in our library
505.
Wu Z. McGoogan J. M. (2020 ). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323 (13), 123942.
Not in our library10.1001/jama.2020.2648
506.
Wu F. Wang A. Liu M. Wang Q. Chen J. Xia S. (2020 ). Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. MedRxiv preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2.full.pdf.
Not in our library10.1101/2020.03.30.20047365
507.
Xiang Y. T. Yang Y. Li W. Zhang L. Zhang Q. Cheung T. (2020 ). Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry 7 (3), 228–229.
Not in our library10.1016/s2215-0366(20)30046-8
508.
Xinhua (2020 a). Uganda braces for economic impact of COVID-19. Available at: http://www.xinhuanet.com/english/2020-03/20/c_138898637.htm.
Not in our library
509.
Xinhua (2020 b). China's Jack Ma gives Zambia COVID-19 medical supplies. Available at: https://www.focac.org/eng/zfgx_4/jmhz/t1760745.htm.
Not in our library
510.
Xu X. Ong Y. K. Wang D. Y. (2020 ). Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Mil. Med. Res. 7 (1), 22.
Not in our library10.1186/s40779-020-00251-x
511.
Yang Y. (2020 ). Use of herbal drugs to treat COVID-19 should be with caution. Lancet 395 (10238), 1689–1690.
Not in our library10.1016/s0140-6736(20)31143-0
512.
Yao H. Chen J. H. Xu Y. F. (2020 ). Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry 7 (4), e21.
Not in our library10.1016/s2215-0366(20)30090-0
513.
Zhang C. Wu Z. Li J. W. Zhao H. Wang G. Q. (2020 ). The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents 105954, 1–6.
Not in our library10.1016/j.ijantimicag.2020.105954
514.
Zhang L. Yu J. Zhou Y. Shen M. Sun L. (2020 ). Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19). Am. J. Chin. Med. 48 (4), 763–777.
Not in our library10.1142/s0192415x2050038x
515.
Zheng Z. Peng F. Xu B. Zhao J. Liu H. Peng J. (2020 ). Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infection.
Not in our library10.1016/j.jinf.2020.04.021
516.
Zheng S. Q. Yang L. Zhou P. X. Li H. B. Liu F. Zhao R. S. (2020 ). Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res. Soc. Adm. Pharm.
Not in our library10.1016/j.sapharm.2020.03.012
517.
Zhong H. Wang Y. Zhang Z. L. Liu Y. X. Le K. J. Cui M. (2020 ). Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol. Res. 157, 104872.
Not in our library10.1016/j.phrs.2020.104872
518.
Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey · 2020
No notice
519.
Zhou F. Yu T. Du R. Fan G. Liu Y. Liu Z. (2020 ). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395 (10229), 1054–1062.
Not in our library10.1016/s0140-6736(20)30566-3
520.
Zhu Z. Lu Z. Xu T. Chen C. Yang G. Zha T. (2020 ). Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J. Infection 81 (1), e21–ee3.
Not in our library10.1016/j.jinf.2020.03.060
521.
Zurek K. (2020 ). COVID-19: President Akufo-Addo lifts partial lockdown effective Monday. Available at: https://www.graphic.com.gh/news/general-news/prez-akufo-addo-covid-update-7.html.
Not in our library

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.